Preparation method for affinity solid-phase linked long-chain nucleic acid

By using specific compound linkers via affinity solid-phase linking, the problem of difficult synthesis and purification of long-chain nucleic acids in traditional methods has been solved, achieving the preparation of long-chain nucleic acids with high purity and high yield.

WO2026237514A1PCT designated stage Publication Date: 2026-11-19PIXEL BIOSCIENCES (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/083349
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-30
Filing Date
2026-03-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Traditional chemical synthesis cannot efficiently synthesize long-chain nucleic acids, and enzymatic splicing methods generate a large number of byproducts that are difficult to purify completely by HPLC, affecting product purity and yield.

Method used

By using compounds with specific structures as linkers, oligonucleotide fragments are immobilized on a solid support using an affinity solid-phase ligation method. Covalent or non-covalent ligation is then achieved by utilizing affinity and immobilization modifications of the compounds, thereby purifying long-chain nucleic acids.

Benefits of technology

It effectively removes byproducts, improves the purity and yield of long-chain nucleic acids, and simplifies the purification process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026083349_19112026_PF_FP_ABST
    Figure CN2026083349_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to a compound as represented by formula I.
Need to check novelty before this filing date? Find Prior Art

Description

Affinity-based solid-phase ligation method for preparing long-chain nucleic acids Technical Field

[0001] This application relates to the field of biomedicine, specifically to a method for preparing long-chain nucleic acids via affinity solid-phase linkage. Background Technology

[0002] Traditional chemical synthesis cannot achieve long-chain synthesis, while enzymatic methods can splice short oligonucleotides to obtain long-chain linked products. However, multi-segment enzymatic linkage produces a large number of byproducts, and three-segment linkage produces one-segment and two-segment linkage products that have not been fully reacted. It is difficult to completely remove the byproducts by HPLC purification alone, which seriously affects the purity and yield of the product. Therefore, it is necessary to develop a purification method that can effectively remove byproducts. Summary of the Invention

[0003] This application provides a compound as shown in Formula I.

[0004] Wherein, R is a fluorescent group, or a structure as shown in formula (II).

[0005] Ra, Rb, Rc, and Rd are each independently H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 ynyl or substituted C2-C6 ynyl.

[0006] R3 is hydrogen, halogen, hydroxyl, C1-C6 alkoxy or substituted C1-C6 alkoxy;

[0007] R2 and R4 are respectively hydroxyl, hydrogen, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy or substituted C1-C6 alkoxy, phosphate group, etc. Or a hydroxyl protecting group, or a structure as shown in formula (III),

[0008] Where: R 41 and R 42 Each is independently a hydroxyl group, thiol, amino group, protected hydroxyl group, protected thiol group, C1-C6 alkyl group, substituted C1-C6 alkyl group, C1-C6 alkoxy group, substituted C1-C6 alkoxy group, protected amino group, or substituted amino group; R 43 For O or S; R 44 It is a chemical bond, -O-, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl or substituted C2-C6 alkenyl, where n2 is 0 or 1;

[0009] R5 is the base moiety;

[0010] R6 represents O, S, -C(R) 61 (R) 62 - or -OC(R) 61 (R) 62 )-, R 61 and R 62 Each independently represents H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, or substituted [substituent].

[0011] C2-C6 alkenyl, C2-C6 ynyl or substituted C2-C6 ynyl;

[0012] A is a leaving group, and A is attached to a hydroxyl or amino group in R;

[0013] L represents a chemical bond or linker that connects A and B;

[0014] B is a coupling reactive group or a stationary phase.

[0015] In some embodiments, the compound is one of the following structures selected from the following:

[0016] In some embodiments, A is a hydroxyl protecting group or an amino protecting group.

[0017] In some embodiments, the hydroxyl protecting group is an ether protecting group or an ester protecting group.

[0018] In some embodiments, the hydroxyl protecting group is an ether protecting group, including alkoxyalkyl ether protecting groups, alkyl ether protecting groups, and silyl ether protecting groups.

[0019] In some embodiments, the alkyl ether protecting group includes benzyl (Bn), p-methoxybenzyl (PMB), triphenylmethyl (Tr, DMT), methyl (Me), and tert-butyl (t-Bu).

[0020] In some embodiments, the alkoxyalkyl ether protecting group includes methoxymethyl (MOM), trimethoxyethoxymethyl (SEM), and 2-tetrahydropyranyl (THP).

[0021] In some embodiments, the silyl ether protecting group includes trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), and tert-butyldiphenylsilyl (TBDPS).

[0022] In some embodiments, the hydroxyl protecting group is an ester protecting group, including carboxylic acid ester protecting groups, carbonate protecting groups, and sulfonate protecting groups.

[0023] In some embodiments, the carboxylic acid ester protecting group includes acetyl (Ac), benzoyl (Bz), and pivaloyl (Piv).

[0024] In some embodiments, the carbonate protecting group includes 9-fluorenylmethoxycarbonyl (-Fmoc) and 2,2,2-trichloroethoxycarbonyl (-Troc).

[0025] In some embodiments, the sulfonate protecting group includes methanesulfonyl (Ms) and p-toluenesulfonyl (Ts).

[0026] In some embodiments, the hydroxyl protecting group is selected from: acyl-based hydroxyl protecting groups, ether-based hydroxyl protecting groups, acetal-based hydroxyl protecting groups, and silyl ether-based hydroxyl protecting groups, such as methyl, ethyl, benzyl (Bn), phenyl, isopropyl, tert-butyl, allyl, cyclohexyl (cHex), methoxymethyl ether (MOM), 2-tetrahydropyran (THP), tert-butyldimethylchlorosilane (TBDMSCl), TBDPS, TBDMS, 4-methoxybenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-acyloxybenzyl, 2-methylphenyl, 2,6-dimethylphenyl, 2-chlorophenyl, pyridine-2-carboxylate, benzyl ether, p-methoxybenzyl ether, triphenylmethyl ether, diphenylmethyl, 4-methylthio. -1-Butyl, 2-(S-acetylthio)ethyl (SATE), 2-cyanoethyl, 2-cyano-1,1-dimethylethyl (CDM), 4-cyano-2-butenyl, 2-(trimethylsilyl)ethyl (TSE), 2-(phenylthio)ethyl, 2-(triphenylsilyl)ethyl, 2-(benzylsulfonyl)ethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,3-dibromopropyl, 2,2,2-trifluoroethyl, phenylthio, 2-chloro-4-triphenylmethylphenyl, 2-bromophenyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 4-(N-trifluoroacetylamino)butyl, 4-oxopentyl, 4-triphenylmethylaminophenyl, 4-benzylaminophenyl.

[0027] In some embodiments, the amino protecting group is selected from: 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), tert-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz), formyl, acetyl, trihaloacetyl, benzoyl and nitrophenylacetyl, 2-nitrobenzenesulfonyl, phthalimide and dithiosuccinyl.

[0028] In some embodiments, B is an amino, hydroxyl, carboxyl, thiol, aldehyde, ketone, azide, vinyl, acryloyl, thiol ester, isocyanate, isothiocyanate, alkyl halide, sulfonyl halide, epoxide, imine ester, fluorophenyl ester, carbonate, carbodiimide, disulfide, aziridine, or a group that can undergo a coupling reaction with the above groups.

[0029] In some embodiments, B is an amino group or a group capable of undergoing a coupling reaction with an amino group.

[0030] In some embodiments, B is an amino group, an NHS ester, an imine ester, a pentafluorophenyl ester, or a hydroxymethylphosphine.

[0031] In some embodiments, B is a carboxyl group or a group capable of undergoing a coupling reaction with a carboxyl group.

[0032] In some embodiments, B is a carboxyl group or a carbodiimide.

[0033] In some embodiments, B is a thiol group or a group capable of undergoing a coupling reaction with a thiol group.

[0034] In some embodiments, B is a mercapto or maleimide, a haloacetyl group, a pyridine dimerol, a thiosulfonate, or a vinyl sulfone.

[0035] In some embodiments, B is an aldehyde group or a group capable of undergoing a coupling reaction with an aldehyde group.

[0036] In some embodiments, B is an aldehyde group, an acylhydrazine, an alkoxyamine, or an NHS ester.

[0037] In some embodiments, B is an azide or a group capable of coupling with an azide.

[0038] In some embodiments, B is an azide or a group containing an alkynyl group.

[0039] In some embodiments, B is a tetrazine or a group that can react with a tetrazine.

[0040] In some embodiments, B is tetrazine, azide, TCO, DBCO, or BCN.

[0041] In some embodiments, B is 4-formylbenzoate (4FB) or hydrazinotinamide (HyNic).

[0042] In some embodiments, R is a fluorescent group, including but not limited to FAM, HEX, TAMRA, Cy3, Cy5, FITC, VIC, TET, JOE, ROX, Texas Red, Atto 488, Atto 565, Atto 647N, hydroxycoumarin, methoxycoumarin, Alexa fluor, aminocoumarin, Cy2, FAM, Alexa fluor 488, Fluorescein FITC, Alexa fluor 430, JOE, TET, Alexa fluor 532, HEX, VIC, Cy3, TRITC, Alexa fluor 546, Alexa fluor 555, R-phycoerythrin (PE), Rhodamine Red-X, TAMRA, Cy3.5, Rox, Alexa fluor 568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Allophycocyanin, Alexa fluor 633, Cy5, Alexa fluor 660, Cy5.5, TruRed, Alexa fluor 680, NED, SYBR Green I and Cy7.

[0043] In some implementations, L is -(C(R) Xa (R) Xb )) n -, where when X contains methylene units, each of the zero or at least one methylene unit of X is independently controlled by -N(R) Xc )C(O)-、-C(O)N(R Xc )-, -C(O)-, -OC(O)-, -C(O)O-, -NR Xc -, -O-, -S-, -SO-, -SO2-, -P(R Xc )-、-P(=O)(R Xc )-、-N(R Xc SO2-, -SO2N(R) Xc -, -C(=S)-, -C(=NR) Xc -, -N=N-, -C=N-, -N=C- or -C(=N2)- are substitutes; where each RXa R Xb R Xc Each of these can be independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or C 1-6 Aliphatic groups.

[0044] In some embodiments, the base moiety is pyrimidine, substituted pyrimidine, pseudouracil, substituted pseudouracil, purine, hypoxanthine, or substituted purine.

[0045] In some embodiments, the bases are selected from one or more of the following group:

[0046] Xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, dioxane, dioxane, dioxane, dioxane, dioxane, 6-chloropurine nucleoside, N6-methyladenine, methylpseudorazine, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamide-N-allyl]uracil, 5-aminoallyl cytosine, 5-aminoallyl uracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5- Carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formylcytosine, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethylcytosine, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyluracil, 5-propynylaminocytosine, 5-propynylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azouridine, 6-chloropurine, 6-thioguanine, 7-deadenine, 7-deadenine, 7-deaden-7-propylaminoadenine, 7 -Denitro-7-propynylaminoadenine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, Biotin-16-aminoallylcytosine, Biotin-16-aminoallyluracil, 3-5-propynylaminocytosine, 3-6-propynylaminouracil, Cyano-3-aminoallylcytosine, Cyano-3-aminoallyllurapinidine, Cyano-5-6-propynylaminocytosine, Cyano-5-6-propynylaminouracil, Cyano-5-aminoallylcytosine, Cyano-5-aminoallyluracil, Cyano-7-aminoallyluracil, Dabcy 1-5-3-aminoallyl uracil, dethiobiotin-16-aminoallyl uracil, dethiobiotin-6-aminoallyl cytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthine, 3-deadenine, 2,6-diaminoadenine, 2,6-Diaminoguanine, 5-Formamidouracil, 5-Ethynyluracil, N6-Isopentenyladenine (i6A), 2-Methylthio-N6-Isopentenyladenine (ms2i6A), 2-Methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-Methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine,

[0047] (g6A), N6-threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxyvalinecarbamoyladenine (hn6A), 2-methylthio-N6-hydroxyvalinecarbamoyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).

[0048] In some embodiments, when A is attached to a hydroxyl or phosphate group, the structure of -A- is one of the following

[0049] The asterisk (*) represents the part that connects to the oxygen atom.

[0050] In some embodiments, when A is linked to a base, the -A- structure has one of the following characteristics, where "*" represents an exocyclic amino group that links the base.

[0051] The asterisk (*) represents the part that connects the bases.

[0052] In some implementations, the -B structure is one of the following:

[0053] (CH2) m SS-, -SH, -NH2, -COOH

[0054] Where m is an integer from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0055] On the other hand, this application provides an oligonucleotide comprising the aforementioned compound.

[0056] On the other hand, this application provides a method for preparing a target nucleic acid, comprising:

[0057] (1) Provide an extractable fragment having an affinity structure, the affinity structure comprising the compound described above, wherein functional group B is an affinity-modified compound.

[0058] (2) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected;

[0059] (3) The extracted fragments were fixed onto the stationary phase by connecting affinity-modified structures and fixation-modified structures;

[0060] (4) Provide an intermediate segment and connect the intermediate segment to the end of the extracted segment;

[0061] (5) Separate the target nucleic acid from the stationary phase.

[0062] On the other hand, this application provides a method for preparing a target nucleic acid, comprising:

[0063] (1) Provide one or more extract fragments and one or more intermediate fragments, wherein the extract fragment contains the compound as an affinity structure, wherein functional group B is an affinity modification;

[0064] (2) Connect one or more extracted fragments and one or more intermediate fragments to form a mixture of nucleic acid fragments;

[0065] (3) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected;

[0066] (4) By linking the affinity modification and the fixation modification, the nucleic acid fragment containing the target nucleic acid in the nucleic acid fragment mixture is bound to the surface of the stationary phase;

[0067] (5) Separate the target nucleic acid from the stationary phase.

[0068] In some embodiments, the extracted fragment includes a first extracted fragment and a second extracted fragment.

[0069] The first extracted fragment includes a first affinity structure, and the first affinity structure includes a first affinity modification;

[0070] The second extracted fragment includes a second affinity structure, which in turn includes a second affinity modification.

[0071] The first affinity modification and the second affinity modification are different.

[0072] In some embodiments, the stationary phase includes a first stationary phase and a second stationary phase, the first stationary phase including a first stationary modification, wherein the first affinity modification and the first stationary modification can be covalently or non-covalently connected; the second stationary phase includes a second stationary modification, wherein the second affinity modification and the second stationary modification can be covalently or non-covalently connected.

[0073] In some embodiments, the extracted fragment and / or intermediate fragment is a single-stranded nucleic acid fragment or a double-stranded nucleic acid fragment.

[0074] In some embodiments, the extracted fragment and / or intermediate fragment is a single-stranded DNA fragment or an RNA fragment.

[0075] In some embodiments, the extracted fragment and / or intermediate fragment is a DNA double-stranded fragment, an RNA double-stranded fragment, or an RNA / DNA hybrid fragment.

[0076] In some embodiments, one or both ends of the extracted fragment and / or intermediate fragment have a protruding structure, wherein the length of the protruding structure is 2-200 nt.

[0077] In some embodiments, the affinity modification and the fixation modification can be covalently linked.

[0078] In some embodiments, the covalent connection forms a linker, which includes amino-reactive linkers, carboxyl-amino-reactive linkers, thiol-reactive linkers, aldehyde-reactive linkers, photoreactive linkers, or azide-reactive linkers.

[0079] In some embodiments, the linker is an amino-reactive linker, including NHS esters, imine esters, pentafluorophenyl esters, or hydroxymethylphosphine.

[0080] In some embodiments, the linker is a thiol-reactive linker, including maleimide, haloacetyl (bromo-, chloro-, or iodine-), pyridine dimercapto, thiosulfonate, and vinyl sulfone.

[0081] In some embodiments, the linker is an aldehyde-reactive linker, including hydrazides, alkoxyamines, and NHS esters.

[0082] In some embodiments, the linker is a photoreactive linker, including bisacrylidine and aromatic azide.

[0083] In some embodiments, the linker is a click chemistry linker.

[0084] In some embodiments, the affinity structure at the 5' or 3' end of the extracted fragment is located on the 2nd carbon of the 5' or 3' end nucleotide.

[0085] In some embodiments, the affinity structure is a polynucleotide, including the compound as described in any one of claims 1-30, wherein the compound is located at the 5' end or 3' end of the polynucleotide, or between the 5' end and 3' end.

[0086] Other aspects and advantages of this application will readily be apparent to those skilled in the art from the detailed description below. Only exemplary embodiments of this application are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this application enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application pertains. Accordingly, the descriptions in the accompanying drawings and specification of this application are merely exemplary and not restrictive. Attached Figure Description

[0087] The specific features of the invention involved in this application are shown in the appended claims. The features and advantages of the invention can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:

[0088] Figures 1A-1E show examples of single-parent and purification mode 2' modifications.

[0089] Figures 2A-2C show examples of single-parent and purification mode 5' modification.

[0090] Figures 3A-3B show examples of biparental and purification modes.

[0091] Figure 4 shows the single-parent and solid-phase connection method described in this application.

[0092] Figure 5 shows one embodiment of the amphiphilic and solid-phase bonding method described in this application.

[0093] Figure 6 shows one embodiment of the multi-round solid-phase affinity connection method described in this application.

[0094] Figure 7 shows one embodiment of the solid-phase covalent bonding method described in this application.

[0095] Figure 8 shows one embodiment of the multi-round solid-phase covalent linkage purification method described in this application. Detailed Implementation

[0096] The following specific embodiments illustrate the implementation of the invention. Those skilled in the art can easily understand other advantages and effects of the invention from the content disclosed in this specification.

[0097] Terminology Definition

[0098] In this application, the compounds comprise their tautomers, meso compounds, racemates, enantiomers, and / or diastereomers. In this application, the term "diastereomer" generally refers to a stereoisomer having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers can have different physical properties, such as melting point, boiling point, spectral properties, and reactivity. In this application, the terms "tautomer" or "tautomer form" are used interchangeably and generally refer to structural isomers of different energies that can be interconverted through a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions via the rearrangement of some bonding electrons. In this application, the term "meta-form" generally refers to a molecule containing asymmetric atoms but possessing symmetry factors that result in zero total optical rotation within the molecule. The terms "racemic form" or "racemic mixture" refer to a composition consisting of two enantiomers in equimolar amounts.

[0099] In this application, certain atoms of the compounds may appear in more than one isotopic form. For example, hydrogen may appear as protium (…). 1 H), deuterium ( 2 H) and tritium ( 3 Carbon exists in the form of H, and it may exist in three different isotopes (H). 12 C 13 C and 14 C) Naturally occurring. Examples of isotopes that may be incorporated into the compounds of this application include, but are not limited to, those that exist naturally. 15 N、 18 O、 17 O、 18 F, 32 P, 33 P, 129 I, 131 I, 123 I, 124 I, 125 I, or similar isotopes. Therefore, the compounds of this application can be enriched in one or more of these isotopes relative to their natural abundance. As those skilled in the art will know, such isotope-enriched compounds can be used for a variety of purposes. For example, with heavy isotopes such as deuterium (I, or similar isotopes). 2 H) substitution may offer certain therapeutic advantages, possibly due to greater metabolic stability. For example, deuterium (H) 2The natural abundance of deuterium (H) is approximately 0.015%. Therefore, there is approximately one deuterium atom for every 6500 hydrogen atoms in nature. Thus, the deuterium-containing compounds of this application have a deuterium abundance greater than 0.015% at one or more positions (as the case may be). Unless otherwise specified, the structures described in this application may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, compounds whose structures are identical to those of this application except that hydrogen atoms are replaced by deuterium or tritium, or carbon atoms are replaced by carbon-13 or carbon-14, are within the scope of this application.

[0100] In this application, the term "pharmaceutical composition" generally refers to a mixture containing one or more of the compounds described in this application or their physiologically / pharmaceutical-grade salts or prodrugs, along with other chemical components, such as physiologically / pharmaceutical-grade carriers and excipients. Pharmaceutical compositions can facilitate administration to an organism, promote the absorption of the active ingredient, and thereby exert its biological activity. Conventional methods for preparing pharmaceutical compositions are described in the art.

[0101] In this application, the term "alkyl" generally refers to a residue derived from an alkane by removing a hydrogen atom. Alkyl groups can be substituted or unsubstituted, substituted or non-substituted. The term "alkyl" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having residues derived from the removal of hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane, and can be a straight-chain or branched group containing 1 to 20 carbon atoms, for example, containing 1 to 12 carbon atoms, such as a chain alkyl containing 1 to 6 carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, etc. Alkyl groups can be substituted or unsubstituted, alternative or non-substituted. For example, when substituted, the substituent can be replaced at any usable connection point. The substituent can be independently selected from one or more substituents chosen from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo, for example, it can be hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(=O)H, -CO2H, -C(=O)C(=O)H, -C(=O)CH2C(=O)H, -S(=O)H, -C(O)NH2, -SO2NH2, -OC(=O)H, -N(H)SO2H, or C 1-6 Aliphatic groups.

[0102] In this application, the term "diyl" is an organic chemical nomenclature suffix defined by the Chinese Chemical Society's "Principles of Organic Chemistry Nomenclature" (2017), referring to a substituent structural unit that connects two different atoms in the molecular skeleton through two single bonds, corresponding to the English suffix -diyl.

[0103] In this application, the term "alkylene" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane. It can be a straight-chain or branched group containing 1 to 20 carbon atoms. For example, the term "methylene" can refer to a residue derived from the removal of two hydrogen atoms from a 1-carbon group. The methylene group can be substituted or unsubstituted, substituted or non-substituted; for example, containing 1 to 12 carbon atoms, such as an alkylene group containing 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2-), 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-). The alkylene group can be substituted or unsubstituted, alternative or non-alternative. For example, when substituted, the substituent can be substituted at any usable connection point. The substituent can be independently selected from one or more substituents chosen from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo, for example, it can be hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or C1-6 aliphatic groups. The methylene or alkylene groups can be substituted or unsubstituted.

[0104] In this application, the term "alkenyl" generally refers to a straight-chain or branched hydrocarbon group containing one or more double bonds. Exemplary examples of alkenyl groups include allyl, homoallyl, vinyl, crotonyl, butenyl, pentenyl, and hexenyl. Exemplary examples of C2-6 chain alkenyl groups having more than one double bond include butadienyl, pentadienyl, hexadienyl, and hextrienyl, as well as their branched forms. The unsaturated bond (double bond) can be located at any position on the carbon chain. Alkenyl groups can be substituted or unsubstituted.

[0105] In this application, the term "alkenyl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkene. Examples include allylene, vinylene, butenylene, pentenylene, and hexenylene. Alkenyl groups can be substituted or unsubstituted.

[0106] In this application, the term "alkynyl" generally refers to an unsaturated straight-chain or branched alkynyl group, such as ethynyl, 1-propynyl, propynyl, butynyl, etc. The alkynyl group can be substituted or unsubstituted.

[0107] In this application, the term "ynynyl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkyne. For example, it can be ethynyl, propynyl, propynyl, butynyl, etc. The ynynyl group can be substituted or unsubstituted.

[0108] In this application, the term "aryl" generally refers to a residue derived from the removal of a hydrogen atom from an aromatic ring. The term "aromatic ring" can refer to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) having a conjugated π-electron system, and can be 6- to 10-membered, such as benzene and naphthalene. The aromatic ring can be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring. The aryl group can be substituted or unsubstituted, and when substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio. The aryl group can be substituted or unsubstituted.

[0109] In this application, the term "arylene" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an aromatic ring. For example, it could be phenylene or naphthylene. The arylene can be substituted or unsubstituted.

[0110] In this application, the term "heteroaryl" generally refers to a residue derived from the removal of a hydrogen atom from a carbon atom of a heteroaryl ring. The term "heteroaryl ring" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur, and nitrogen. The heteroaryl group may be 5 to 10-membered, or 5- or 6-membered, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring may be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring connected to the parent structure is the heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted. When substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. The heteroaryl group can be substituted or unsubstituted.

[0111] In this application, the term "heteroaryl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of a heteroaryl ring. Examples include iminofuranyl, iminothienyl, iminopyridyl, iminopyrroleyl, iminopyridyl, iminopyrazinyl, iminopyrazolyl, iminotetrazoleyl, etc. Heteroaryl groups can be substituted or unsubstituted.

[0112] In this application, the term "alicyclic group" generally refers to a residue derived by removing a hydrogen atom from the same carbon atom or multiple different carbon atoms of an aliphatic ring. The term "cycloalkane" generally refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon having a carbocyclic ring containing 3 to 20 carbon atoms, or 3 to 12 carbon atoms, or 3 to 10 carbon atoms, or 3 to 8 carbon atoms. Non-limiting examples of alicyclic groups include cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptanetrienyl, cyclooctane, etc.; polycyclic carbocyclic rings may include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. Alicyclic groups can be substituted or unsubstituted. In this application, the term "carbocyclic group" generally refers to a residue derived by removing a hydrogen atom from a carbon atom of a carbocyclic ring. The term "carbocyclic ring" generally refers to saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbons containing 3 to 20 carbon atoms, 3 to 12 carbon atoms, 3 to 10 carbon atoms, or 3 to 8 carbon atoms. Non-limiting examples of monocyclic carbocyclic rings include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptanetriene, cyclooctane, etc.; polycyclic carbocyclic rings can include spirocyclic, fused, and bridged rings. The carbocyclic group can be substituted or unsubstituted. In some cases, alicyclic and carbocyclic rings can be used interchangeably.

[0113] In this application, the term "partially unsaturated" generally refers to a cyclic structure in which the cyclic molecules contain at least one double or triple bond. The term "partially unsaturated" encompasses cyclic structures with multiple unsaturations, but is not intended to include aromatic or heteroaromatic rings as defined in this application. The term "unsaturated" indicates that a portion has one or more degrees of unsaturation.

[0114] In this application, the term "alicyclic group" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alicyclic ring. For example, it can be cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptanetrienyl, cyclooctyl, etc.; the polycyclic carbocyclic ring can include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. The alicyclic group can be substituted or unsubstituted.

[0115] In this application, the term "aliphatic heterocyclic group" generally refers to a stable, non-aromatic 3-7 member monocyclic carbon ring structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. These cyclic structures can be saturated or partially saturated, and in addition to carbon atoms, they contain one or more heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it may contain 1-4 heteroatoms as defined above. When used to refer to atoms in an aliphatic heterocyclic ring structure, the term "nitrogen" may include nitrogen that has undergone a substitution reaction. For example, an aliphatic heterocyclic group may include "heterocyclic alkyl group," which may refer to a stable, non-aromatic 3-7 member monocyclic alkyl structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. In addition to carbon atoms, these cyclic structures contain one or more heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it may contain 1-4 heteroatoms as defined above. Heterocyclic alkyl groups can be substituted or unsubstituted. Alicyclic groups can be substituted or unsubstituted.

[0116] In this application, the term "allelic heterocyclic group" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alicyclic ring. Allelic heterocyclic groups can be substituted or unsubstituted.

[0117] In this application, the terms “optional” or “optionally” generally refer to an event or environment described subsequently that may but does not have to occur, and the description includes situations in which the event or environment occurs or does not occur. For example, “optionally alkyl-substituted heterocyclic group” means that an alkyl group may but does not have to be present, and the description can include cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0118] In this application, the term "substituted" generally refers to one or more hydrogen atoms in a group, for example, up to five, or for example, one to three hydrogen atoms, independently substituted by the corresponding number of substituents. Substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).

[0119] In this application, as those skilled in the art will know, terms such as "alkyl," "alkenyl," and "cycloalkyl" may be preceded by an identifier indicating the number of atoms present in the group under specific conditions, for example, C1-C4 alkyl, C3-C7 cycloalkoxy, C1-C4 alkylcarbonylamino, etc., and the subscript number following "C" indicates the number of carbon atoms present in the group. For example, C3 alkyl refers to an alkyl group having three carbon atoms (e.g., n-propyl, isopropyl); C 1-10 In this context, the members of the group can have any number of carbon atoms falling within the range of 1-10.

[0120] One or more hydrogen atoms in a group, for example, up to five, or for example, one to three hydrogen atoms, are independently replaced by the corresponding number of substituents. The substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).

[0121] In this application, the term "compound" generally refers to a substance having two or more different elements. For example, the compound in this application can be an organic compound, a compound with a molecular weight of less than 500, less than 1000, more than 1000, or more than 10,000 or 100,000. In this application, a compound can also refer to a compound linked by chemical bonds. For example, it can be a compound in which one or more molecules with a molecular weight of less than 1000 are linked by chemical bonds to a biological macromolecule, such as a polysaccharide, protein, nucleic acid, polypeptide, etc. For example, the compound in this application can include a compound in which a protein is linked to one or more molecules with a molecular weight of less than 1000, a compound in which a protein is linked to one or more molecules with a molecular weight of less than 10,000, or a compound in which a protein is linked to one or more molecules with a molecular weight of less than 100,000.

[0122] In this application, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements. The terms "above" and "below" generally refer to situations that include the stated number.

[0123] In this application, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.

[0124] As used in this article, the term "protecting group" can refer to any atom or group of atoms introduced into a molecule to prevent existing groups in the molecule from undergoing undesirable chemical reactions, which can be removed to leave unprotected groups.

[0125] The hydroxyl protecting group can be, for example, the hydroxyl protecting group commonly used to protect the ribose structure in the synthesis of RNA or its derivatives, see also Green et al., Protective Groups in Organic Synthesis, 3rd Edition, 1999, John Protecting groups described in the Wiley & Sons, Inc. literature include, for example: acetyl, phenoxyacetyl, neopentanoyl, benzyl, 4-methoxybenzyl, benzoyl, triphenylmethyl, 4,4'-dimethoxytriphenylmethyl (DMTr), monomethoxytriphenylmethyl (MMTr), 9-phenyl-xanthen-9-yl, 9-(p-tolyl)-xanthen-9-yl, trimethylsilyl, tert-butyldimethylsilyl (TBDMS), cyanomethoxymethyl, 2-(cyanoethoxy)ethyl, cyanoethoxymethyl, etc., preferably 4,4'-dimethoxytriphenylmethyl (DMTr, 4,4'-dimethoxytrityl).

[0126] The "ether protecting group" of a hydroxyl group refers to a protecting group that can form an ether with the hydroxyl group.

[0127] The "silyl ether protecting group" for a hydroxyl group refers to a protecting group capable of forming a silyl ether with the hydroxyl group. Silyl ether protection is usually carried out by reacting the corresponding chlorosilane with an alcohol under alkaline conditions, for example: TBS-Cl / imidazole. The removal of silyl ether protecting groups can be performed under acidic or alkaline conditions. Silyl ethers with different alkyl groups have different degrees of sensitivity to acids or bases, and the deprotection conditions differ accordingly. The relative stability order of several common silyl ether protecting groups to acid hydrolysis is: TMS < TES < TBS < TIPS < TBDPS; the relative stability order to bases is: TMS < TES < TBS ≈ TBDPS < TIPS. In addition, due to the strong affinity between fluorine and silicon atoms, fluoride anion (F - ) becomes the most commonly used deprotection method, and related deprotection reagents include tetraalkylammonium fluoride, such as TBAF (tetrabutylammonium fluoride) / THF, pyridinium hydrofluoride, HF / MeCN, and the like.

[0128] The "alkyl ether protecting group" of a hydroxyl group refers to a protecting group that can form an alkyl ether with the hydroxyl group. Commonly used protecting groups for alkyl ethers include benzyl (Bn), p-methoxybenzyl (PMB), triphenylmethyl (Tr, DMT), methyl (Me), and tert-butyl (t-Bu). Benzyl is a commonly used ether protecting group, usually introduced using the Williamson synthesis, obtained by reacting a haloalkane with the corresponding sodium alkoxide in DMF or THF. In actual synthesis, a suitable base is selected to react with BnCl or BnBr depending on the acidity of the different hydroxyl groups. The benzyl group is usually removed by hydrogenolysis, with Pd / C being the most commonly used catalyst. The hydrogen source can be hydrogen gas, or it can be cyclohexene, ammonium formate, isopropanol, etc. Alternatively, benzyl can also be removed under acidic conditions such as the presence of Lewis acids TMSI or FeCl3. The introduction and removal methods for p-methoxybenzyl (PMB) are similar to those for benzyl. PMB protecting groups are often removed in trifluoroacetic acid (TFA) (e.g., TFA, CH2Cl2, rt). In addition, common removal methods for PMB include oxidation, such as DDQ / CH2Cl2-H2O and CAN / MeCN. Therefore, p-methoxybenzyl can be selectively removed in the presence of benzyl. Commonly used triphenylmethyl protecting groups include triphenylmethyl (Tr) and 4,4'-dimethoxytriphenylmethyl (DMT). Due to their steric hindrance, they are usually used to protect primary alcohols. Triphenylmethyl ethers are commonly introduced using systems such as Tr-Cl, DMAP, Py, and Tr-Cl / Et3N / DMAP, CH2Cl2. Removal methods generally employ acidic conditions, such as TsOH / MeOH and AcOH, or can be removed by Pd / C hydrogenation. 4,4'-dimethoxytriphenylmethyl is also commonly used to protect hydroxyl groups, and its introduction and removal methods are similar to those for Tr. Methyl ethers are mainly introduced using reagents such as dimethyl sulfate, iodomethane, and diazomethane. Common systems include NaH / Me₂SO₄ and NaH / MeI. Methyl ethers are relatively stable and difficult to remove. They are typically demethylated using the BBr₃ / CH₂Cl₂ system, but TMSI / CH₂Cl₂ or MeCN systems can also be used. Compared to alcohol hydroxyl groups, phenolic hydroxyl groups are often protected with methyl ethers and are easier to remove.

[0129] The hydroxyl group with an alkoxyalkyl ether protecting group, also known as an acetal protecting group, is a commonly used type of protecting group. Commonly used protecting groups include methoxymethyl (MOM), trimethoxyethoxymethyl (SEM), and 2-tetrahydropyranyl (THP). These protecting groups are sensitive to acids and are usually removed under acidic conditions. The introduction of protecting groups like MOM and SEM is mostly done under basic conditions, reacting the corresponding chlorinated derivative with the alcohol; common systems include NaH / THF and DIEA / CH2Cl2. Deprotection is carried out under acidic conditions. MOM requires a strong acid, while SEM is more sensitive to acids and can be removed under weakly acidic conditions. Furthermore, because the SEM protecting group contains a silicon group, it can also be removed using TBAF.

[0130] The "ester protecting group" of a hydroxyl group refers to a protecting group that can form an ester with the hydroxyl group.

[0131] Commonly used protecting groups for carboxylic acid esters include acetyl (Ac), benzoyl (Bz), and pivaloyl (Piv), which are widely used in the synthesis of carbohydrates and peptides. The methods for introducing acyl groups are generally similar, involving the reaction of the corresponding acyl chloride or acid anhydride with an alcohol in the presence of a base (mainly pyridine or triethylamine) to obtain the corresponding ester. If the reaction is too slow, especially with sterically hindered substrates, DMAP can be added to accelerate the reaction. Additionally, in polyhydroxy substrates, pivaloyl chloride can selectively protect primary alcohols. Generally, ester groups can be removed by hydrolysis under basic conditions, such as with K₂CO₃, NH₃, or hydrazine hydrate. The order of hydrolytic ability of the acyl groups mentioned above is approximately: pivaloyl (Piv) < benzoyl (Bz) < acetyl (Ac). Taking advantage of the ease of hydrolysis of these protecting groups, the acetyl group can be selectively removed in the presence of pivaloyl.

[0132] Carbonates are also a means of protecting hydroxyl groups. They can be removed by alkaline hydrolysis or by using a second alkyl substituent. Commonly used protecting groups include 9-fluorenylmethoxycarbonyl (-Fmoc) and 2,2,2-trichloroethoxycarbonyl (-Troc).

[0133] Sulfonate protecting groups are mainly used to protect carbohydrate compounds, and can also be used in certain specific compounds. Commonly used ones include methanesulfonyl (Ms) and p-toluenesulfonyl (Ts), but in many cases, the introduction of sulfonyl groups (OMs, OTs) is more often used as leaving groups in the reaction.

[0134] The amino protecting group may be, but is not limited to, fluorenemethyloxycarbonyl (Fmoc), tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), optionally substituted acyl, trifluoroacetyl (TFA), benzyl, triphenylmethyl (Tr), 4,4'-dimethoxytriphenylmethyl (DMTr) or toluenesulfonyl (Ts), preferably fluorenemethyloxycarbonyl (Fmoc).

[0135] The term "phosphate group" is a phosphoric acid-containing group, which in some cases can be negatively charged. The charge is evenly distributed between the two unlinked oxygen atoms. In this application, the phosphate group can be linked to multiple L atoms, or it can be linked to an L atom and an oligonucleotide. However, the phosphate group can be modified by replacing one of the oxygen atoms with different substituents. Examples of modified phosphate groups include thiophosphate, phosphoroselenate, boron phosphate, boron phosphate ester, hydrophosphonate, aminophosphate, alkyl or aryl phosphonate, and phosphate triester. In dithiophosphate, both unlinked oxygen atoms are replaced by sulfur. The oxygen in the phosphodiester bond can be replaced by any one of S, Se, B, C, H, N, or OR (R is alkyl or aryl). The phosphate linker can also be modified by replacing the linking oxygen atoms with nitrogen (bridged aminophosphate), sulfur (bridged thiophosphate), and carbon (bridged methylene phosphonate).

[0136] As used herein, the term "phosphorus-containing reactive group" refers to a phosphorus-containing group capable of reacting with a hydroxyl or amino group contained in another molecule, particularly in another nucleotide unit or another nucleotide analog, via a nucleophilic attack reaction. Typically, such a reaction produces an ester-type nucleoside bond linking the nucleotide unit or nucleotide analog unit to another nucleotide unit or nucleotide analog unit. These phosphorus-containing reactive groups are known in the art and contain phosphorus atoms in the PIII or PV valence states, including but not limited to phosphorus amides, H-phosphonates, phosphate triesters, and phosphorus-containing chiral auxiliaries. Examples of phosphorus-containing reactive groups include: 2-cyanoethoxy-N,N-diisopropylaminophospho, 2-propenoxy-N,N-diisopropylaminophospho, methoxy-N,N-diisopropylaminophospho, bis(diisopropylaminophospho), etc.

[0137] 2-Cyanethoxy-N,N-diisopropylaminophospho,

[0138] 2-Acryloxy-N,N-Diisopropylaminophospho,

[0139] Methoxy-N,N-diisopropylaminophosphine,

[0140] Bis(diisopropylamino)phospho, etc.

[0141] In one embodiment, the phosphorus-containing reactive group is...

[0142] As used in this invention, the term "fluorescent group" refers to a chemical group containing a fluorescent label, which is a substance that, when excited by light of a specific wavelength, such as 520 nm, can absorb that wavelength and then re-emit colored visible light. The fluorescent group is typically covalently bound to other molecules to detect the presence of those molecules in the environment. Common reactive groups include, but are not limited to, amine-reactive isothiocyanate derivatives, such as FITC and TRITC (derived from fluorescein and rhodamine), amine-reactive succinimide esters, such as NHS-fluorescein, and sulfhydryl-reactive maleimide-activated fluorescein, such as fluorescein-5-maleimide. In some embodiments, the fluorescent group is covalently linked to a nucleotide monomer or oligonucleotide chain to detect the presence of the nucleotide monomer or oligonucleotide chain in the intracellular environment. The fluorescent group can be indirectly linked to the nucleotide monomer or oligonucleotide chain via other nucleotide-modifying molecules, or directly linked to the pentose sugar, base, and / or phosphate group of the nucleotide molecule. In some embodiments, the fluorescent group may be labeled with 6-carboxyfluorescein (FAM).

[0143] Fluorescent groups include fluorescent dyes containing xanthan dyes, such as fluorescein and rhodamine dyes, such as fluorescein isothiocyanate (FITC), 6-carboxyfluorescein (usually abbreviated as FAM and F), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G5 or G5), 6-carboxyrhodamine-6G (R6G6 or G6), and rhodamine 110; cyanine dyes, such as Cy3, Cy5, and Cy7 dyes; coumarin dyes, such as umbelliferone; and benzimidazole dyes, such as Hoechst. 33258; phenanthridine dyes, such as Texas Red; ethidium bromide dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethystyl dyes, such as cyanine dyes, like Cy3 and Cy5; BODIPY dyes and quinoline dyes. Specific fluorescent dyes commonly used in certain applications include: pyrene, coumarin, diethylaminocoumarin, FAM, chlorotriazinylfluorescein, R110, eosin, JOE, R6G, tetramethylrhodamine, TAMRA, lissamine, ROX, naphthalenefluorescein, Texas Red, naphthalenefluorescein, Cy3, and Cy5, etc. Suitable and distinguishable fluorescent label pairs for this research method include Cy-3 and Cy-5 (Amersham, Piscataway, NJ), Quasar 570 and Quasar 670 (Biosearch Technology, Novato, CA), with preference given to the following four Alexa dyes: Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 594, and Alexa Fluor 647 (Molecular Probes, Eugene, Oregon). Atto dyes: Atto488, Atto565, Atto594, Atto647N, Atto750 (Atto-Tec GmbH); BODIPY V-1002 and BODIPY V1005 (Molecular Probes, Eugene, Oregon); POPO-3 and TOTO-3 (Molecular Probes, Eugene, Oregon). For more suitable, distinguishable, and detectable markers, see Kricka et al. (Ann Clin Biochem. 39:114-29, 2002).

[0144] In this application, the terms "nucleic acid" and "polynucleotide" are used interchangeably and refer to a polymeric form of a nucleotide (deoxyribonucleotide or ribonucleotide or the like) of any length. The polynucleotide may have any three-dimensional structure and perform any function. The polynucleotide may contain one or more modifications or substitutions at one or more bases, sugars, and / or phosphate esters as described in this application or known in the art. In some embodiments, the modified nucleotide may be a methylated nucleotide or a nucleotide analog. In some embodiments, the nucleotide structure may be modified before or after the assembly of the polynucleotide polymer. The polynucleotide may be modified post-polymerization, for example, by coupling with a labeled component. The polynucleotide polymer may be blocked by a non-nucleotide component. In this application, the terms "nucleic acid" and "polynucleotide" can refer to double-stranded and single-stranded molecules. Unless otherwise stated or required, any embodiment of a polynucleotide in this application includes both double-stranded forms and each of two complementary single-stranded forms known or predicted to constitute a double-stranded form. For example, polynucleotides can include, but are not limited to: genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, siRNA, miRNA, shRNA, RNAi reagents and primers.

[0145] In this application, the term "oligonucleotide" generally refers to a polymer composed of multiple nucleotide residues (deoxyribonucleotides or ribonucleotides, or their associated structural variants or synthetic analogs) linked by phosphodiester bonds (or their associated structural variants or synthetic analogs). Therefore, while the term "oligonucleotide" generally refers to a nucleotide polymer in which the nucleotide residues and their linkages are naturally occurring, it should be understood that the scope of the term also includes various analogs, including but not limited to: peptide nucleic acids (PNAs), aminophosphates, thiophosphates, methylphosphates, 2-O-methylribonucleic acid, etc. The exact size of the molecule may depend on the specific application. Oligonucleotides are generally short in length, typically containing about 10-30 nucleotide residues, but the term can also refer to molecules of any length, although the terms "polynucleotide" or "nucleic acid" are generally used for larger oligonucleotides.

[0146] In some embodiments, the oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and / or unmodified deoxyribonucleosides (DNA) and / or one or more modified nucleotides. The term "modified oligonucleotide" generally means an oligonucleotide comprising at least one modified nucleotide and / or at least one modified nucleotide linked together.

[0147] In this application, the term "modified nucleoside" generally refers to a nucleoside that contains at least one chemical modification compared to naturally occurring RNA or DNA nucleosides. Modified nucleosides comprise modified sugar moieties and / or modified nucleobases.

[0148] In this application, the term "nucleobase" generally refers to a heterocyclic pyrimidine or purine compound, which is a component of all nucleic acids and includes adenine (a), guanine (g), cytosine (c), thymine (t), and uracil (u). Nucleotides may include modified nucleotides or nucleotide mimics, base-free sites (Ab or X), or substitute substituted portions. As used in this application, "nucleobase sequence" generally refers to a sequence of consecutive nucleobases independent of any sugar, linking, or nucleobase modification. The terms "unmodified nucleobase" or "naturally occurring nucleobase" generally refer to naturally occurring heterocyclic nucleobases in RNA or DNA: the purine bases adenine (a) and guanine (g); and thymine (t), cytosine (c) (including 5-methylc), and uracil (u). "Modified nucleobase" generally refers to any nucleobase that is not naturally occurring.

[0149] The term "solid phase" is used to refer to any non-aqueous matrix to which one or more ligands may attach, or, in size repulsion chromatography, it may refer to the gel structure of a resin. The solid phase can be any matrix capable of attaching ligands in such a manner, such as purification columns, discontinuous phases of discrete particles, membranes, filters, gels, etc. Examples of substances that can be used to form the solid phase include polysaccharides (e.g., agarose and cellulose) and other mechanically stable matrices such as silica (e.g., controlled-pore glass), poly(divinyl styrene), polyacrylamide, ceramic particles, and their derivatives. This invention is not limited to any specific solid phase material used in the chromatographic step; those skilled in the art may choose suitable solid phase materials for use in this invention.

[0150] The term "nucleotide" generally refers to a glycoside or glycoside analog comprising a sugar moiety, a base moiety, and a covalently linked group, and covers naturally occurring nucleotides (e.g., DNA or RNA) as well as non-naturally occurring nucleotides comprising modified sugar and / or base moieties. In this application, the term "nucleoside linkage" generally refers to a covalent linkage between adjacent nucleosides in an oligonucleotide, which can be a naturally occurring or modified nucleoside linkage. "Naturally occurring nucleoside linkage" refers to a 3' to 5' phosphodiester linkage. "Modified nucleoside linkage" refers to any nucleoside linkage other than a naturally occurring nucleoside linkage.

[0151] The term "single chain" as used in this application refers to a single polynucleotide chain formed by the linkage of multiple nucleotide monomers.

[0152] Nucleotide monomers can be ribonucleotide monomers, and the resulting single strand can be an RNA single strand; nucleotide monomers can also be deoxyribonucleotide monomers, and the resulting single strand can be a DNA single strand.

[0153] The "hybrid double strand" described in this application refers to a double-stranded nucleic acid molecule composed of two anticomplementary polynucleotide single strands, which can be linked together by hydrogen bonds formed between one or more complementary bases on the double strands. Depending on the type of single strand, it can be classified as DNA-DNA double strand (containing two DNA single strands) or RNA-DNA double strand (containing one DNA single strand and one RNA single strand). In some embodiments, the two anticomplementary polynucleotide single strands can be perfectly complementary, i.e., there are no unpaired bases at either end of the single strand. In some embodiments, the two anticomplementary polynucleotide single strands can be imperfectly complementary, i.e., there are one or more unpaired bases at either end or one end of either single strand.

[0154] The term "ligase" as used in this application refers to an enzyme or polypeptide capable of catalyzing the formation of phosphodiester bonds between nucleotides, thereby linking nucleic acid fragments together, between nucleic acid fragments and free nucleotides, or between bases of free nucleotides. The ligase polypeptide catalyzes the ligation reaction on single-stranded or hybridized double-stranded nucleic acids, and the ligase polypeptide catalyzes the formation of phosphodiester bonds at the sticky or blunt ends of the nucleic acid strand. The ligase polypeptide can be a ligase, such as DNA ligase or RNA ligase, or a functional fragment of the aforementioned ligases, wherein the functional fragment can be any fragment of the aforementioned ligases capable of performing the ligation function. The ligase polypeptide can be ATP-dependent and / or NAD+-dependent. + Dependent on specific types. The ligase polypeptide may be derived from eukaryotes, prokaryotes, and / or bacteriophages, including but not limited to one or more of the following groups: T4 DNA ligase, T4 RNA ligase, T3 DNA ligase, T7 DNA ligase, eukaryotic DNA ligase I, eukaryotic DNA ligase III, eukaryotic DNA ligase IV, E. coli DNA ligase, Hi-T4. TM DNA ligase, Salt-T4 DNA ligase, 9°N TM DNA ligase, Taq DNA ligase, HiFi Taq DNA ligase The ligase includes thermostable 5' App DNA / RNA ligase, RtcB ligase, and PBCV DNA ligase. The ligase polypeptide further includes isoenzymes of any of the above-mentioned ligases and / or fragments of any of the ligases capable of performing ligation functions.

[0155] Affinity modifications and fixation modifications refer to a pair of modifications that interact covalently or non-covalently, allowing the extracted sequence to be fixed on a solid phase. Affinity modifications are present on the extracted fragment, while fixation modifications are present on the stationary phase.

[0156] The term "protruding structure," "sticky end," or "protruding tip" as used in this application refers to the end of one or both sides of a nucleic acid hybrid double strand, where one strand has one or more protruding unpaired nucleotides. The protruding structure can be located at either end of either strand of the nucleic acid double strand. For example, when the hybrid double strand is DNA-RNA hybrid double strand, the protruding structure can be located at one end of the RNA single strand. In some embodiments, when the hybrid double strand is DNA-RNA hybrid double strand, only one end of the RNA single strand contains the protruding structure, while the other end is a blunt end. In some embodiments, when the hybrid double strand is DNA-RNA hybrid double strand, both ends of the hybrid double strand contain the protruding structure. The protruding structure can include a single unpaired nucleotide or multiple unpaired nucleotides, such as 6-20 unpaired nucleotides. In some embodiments, the protruding structure contains 6-16 unpaired nucleotides. The protruding structure is a linear structure without any secondary structure.

[0157] The term "blunt end" as used in this application generally refers to an end on a hybrid double helix where the bases are completely complementary, meaning there are no unpaired bases at the blunt end of the hybrid double helix. A hybrid double helix can have one blunt end or both blunt ends. These blunt ends can be ligated under the catalysis of ligases, such as T4 DNA ligase. The ligation efficiency of blunt ends is much lower than that of sticky ends; during zigzag structure ligation, the ligation process seeks out a sticky end to pair with. Furthermore, blunt ends do not contain 5' phosphate groups, so blunt end ligation is not possible.

[0158] In this application, the term "about" is used to mean approximately, around, roughly, or about. When the term "about" is used in conjunction with a numerical value or range, it can modify and expand the range by extending the upper and lower limits of the listed numerical value or range. Typically, the term "about" is used herein to modify a numerical value by a variation of 10%, 8%, 5%, 2%, 1%, 0.5%, or 0.1% above or below the specified value.

[0159] Invention Details

[0160] This application provides a compound as shown in Formula I.

[0161] The compound represented by Formula I can be a monomer or a compound containing the structure of Formula I, such as an oligonucleotide.

[0162] Wherein, R is a fluorescent group, or a structure as shown in formula (II).

[0163] Ra, Rb, Rc, and Rd are each independently H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 ynyl or substituted C2-C6 ynyl.

[0164] In some implementations, Ra, Rb, Rc, and Rd can be H.

[0165] R3 can be hydrogen, halogen, hydroxyl, C1-C6 alkoxy, or a substituted C1-C6 alkoxy. For example, R3 can be chlorine, fluorine, methoxy, etc.

[0166] R2 and R4 are respectively hydroxyl, hydrogen, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy or substituted C1-C6 alkoxy, phosphate group, etc. Or a hydroxyl protecting group, or a structure as shown in formula (III),

[0167] Where: R 41 and R 42 Each is independently a hydroxyl group, thiol, amino group, protected hydroxyl group, protected thiol group, C1-C6 alkyl group, substituted C1-C6 alkyl group, C1-C6 alkoxy group, substituted C1-C6 alkoxy group, protected amino group, or substituted amino group; R 43 For O or S; R 44 n is a chemical bond, a C1-C6 alkyl group, or a substituted C1-C6 alkyl group, where n2 is 0 or 1.

[0168] For example, R2 can be a hydroxyl group, a phosphate group, or...

[0169] For example, R4 can be a hydroxyl group, a phosphate group, or a phosphorus-containing reactive group, such as 2-cyanoethoxy-N,N-diisopropylaminophospho, 2-propenoxy-N,N-diisopropylaminophospho, methoxy-N,N-diisopropylaminophospho, bis(diisopropylaminophospho), etc. In one embodiment, the phosphorus-containing reactive group is...

[0170] R5 represents the base moiety. The base moiety consists of nitrogenous bases that make up the nucleotide. The base moiety includes nucleobases such as cytosine, guanine, adenine, thymine, uracil, pseudouracil, and modified nucleobases, such as m5C (5-methylcytidine), m5U (5-methyluridine), m6A (N6-methyladenosine), s2U (2-thiouridine), Um (2'-O-methyluridine), m1A (1-methyladenosine); m2A (2-methyladenosine); Am (2-1-O-methyladenosine); ms2m6A (2-methylthio-N6-methyladenosine); i6A (N6-isopentenyladenosine); ms2i6A (2-methylthio-N6-isopentenyladenosine); io6A (N6-(cis-hydroxyisopentenyl)adenosine); ms2io6A (2-methylthio- N6-(cis-hydroxyisopentenyl)adenosine); g6A (N6-glycylcarbamoyladenosine); t6A (N6-threonylcarbamoyladenosine); ms2t6A (2-methylthio-N6-threonylcarbamoyladenosine); m6t6A (N6-methyl-N6-threonylcarbamoyladenosine); hn6A (N6-hydroxyn-valinecarbamoyladenosine); ms2hn6A (2-methylthio-N6-hydroxyn-valinecarbamoyladenosine); Ar(p)(2'-O-ribosyladenosine (phosphate)); I (inosine); m11 (1-methylinosine); m'Im (1,2'-O-dimethylinosine); m3C (3-methyl Cytidine); Cm (2T-O-methylcytidine); s2C (2-thiocytidine); ac4C (N4-acetylcytidine); f5C (5-fonnylcytidine); m5Cm (5,2-O-dimethylcytidine); ac4Cm (N4-acetyl-2-O-methylcytidine); k2C (lysine); m1G (1-methylguanosine); m2G (N2-methylguanosine); m7G (7-methylguanosine); Gm (2'-O-methylguanosine); m22G (N2,N2-dimethylguanosine); m2Gm (N2,2'-O-dimethylguanosine); m22Gm (N2,N2,2'-trimethylguanosine); Gr(p)(2'-O-ribosylguanosine (phosphate ester (p)) hosphate); yW (wybutosine); o2yW (peroxy-wybutosine); OHyW (hydroxy-wybutosine); OHyW* (modified hydroxy-wybutosine); imG (wyosine); mimG (methylguanosine); Q (queuosine); oQ (epoxyqueuosine); galQ (galactosylqueuosine); manQ (mannosylqueuosine); preQo (7-cyano-7-deazonoguanosine); preQi (7-aminomethyl-7-deazonoguanosine); G (archopurin); D (dihydrouridine); m5Um (5,2'-O-dimethyluridine); s4U (4-thiouridine);m5s2U (5-methyl-2-thiouridine); s2Um (2-thio-2'-O-methyluridine); acp3U (3-(3-amino-3-carboxypropyl)uridine); ho5U (5-hydroxyuridine); mo5U (5-methoxyuridine); cmo5U (uridine 5-oxyacetic acid); mcmo5U (uridine 5-oxyacetic acid methyl ester); chm5U (5-(carboxyhydroxymethyl)uridine); mchm5U (5-(carboxyhydroxymethyl)uridine methyl ester); mcm5U (5-methoxycarbonylmethyluridine); mcm5Um (S-methoxyuridine) 5-Methoxycarbonylmethyl-2-O-methyluricjine); mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine); nm5s2U (5-aminomethyl-2-thiouridine); mnm5U (5-methylaminomethyluridine); mnm5s2U (5-methylaminomethyl-2-thiouridine); mnm5se2U (5-methylaminomethyl-2-selenouridine); ncm5U (5-carbamoylmethyluridine); ncm5Um (5-carbamoylmethyl-2'-O-methyluridine); cmnm5U (5-carboxymethylaminomethyluridine) ); cnmm5Um (5-carboxymethylaminomethyl-2-LO methyluridine); cmnm5s2U (5-carboxymethylaminomethyl-2-thiouridine); m62A (N6,N6-dimethyladenosine); Tm (2'-O-methylinosine); m4C (N4-methylcytidine); m4Cm (N4,2-O-dimethylcytidine); hm5C (5-hydroxymethylcytidine); m3U (3-methyluridine); cm5U (5-carboxymethyluridine); m6Am (N6,TO-dimethyladenosine); rn62Am (N6,N6,O-2-trimethyluridine) m2'7G (N2,7-dimethylguanosine); m2'2'7G (N2,N2,7-trimethylguanosine); m3Um (3,2T-O-dimethyluridine); m5D (5-methyldihydrouridine); f5Cm (5-formyl-2'-O-methylcytidine); m1Gm (1,2'-O-dimethylguanosine); m'Am (1,2-O-dimethyladenosine); tm5s2U (S-taurino-2-thiouridine); imG-14 (4-demethylguanosine); imG2 (isoguanosine);Or ac6A (N6-acetyladenosine), hypoxanthine, inosine, 8-oxo-adenine, its 7-substituted derivatives, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C1-C6)-alkyluracil, 5-methyluracil, 5-(C2-C6)-alkenyluracil, 5-(C2-C6)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C1-C6)- Alkyl cytosine, 5-methyl cytosine, 5-(C2-C6)-alkenyl cytosine, 5-(C2-C6)-alkynyl cytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N2-dimethylguanine, 7-deazaguanine, 8-azaguanine, 7-deaza-7-(C2-C6)alkynylguanine, 8-hydroxyguanine, 6-thioguanine, 8-oxoguanine, 2-aminopurine, 2-amino-6-chloropurine, 2,4-diaminopurine, 2,6-diaminopurine, 8-azapurine, etc.

[0171] R6 represents O, S, C(R) 61 (R) 62 ) or OC(R 61 (R) 62 ), R 61 and R 62 Each of these components is independently H, a halogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C1-C6 alkoxy, a substituted C1-C6 alkoxy, a C2-C6 alkenyl, a substituted C2-C6 alkenyl, a C2-C6 ynyl, or a substituted C2-C6 ynyl. In some embodiments, R6 is given as oxygen.

[0172] A is a leaving group, and A is attached to a hydroxyl or amino group in R.

[0173] L is a chemical bond or linker that connects A and B.

[0174] B is an electrophilic group or a affinity group.

[0175] In some embodiments, R5 has an amino or hydroxyl group, and A is attached to the hydroxyl or amino group in R5.

[0176] In some embodiments, one of R2, R3, or R4 is an -ALB structure, or the hydroxyl group of one of R2, R3, or R4 forms -OALB with the -ALB structure.

[0177] In some embodiments, R2 has an amino or hydroxyl group, and A is connected to the hydroxyl or amino group in R2.

[0178] In some embodiments, the compound is one of the following structures selected from the following:

[0179] In some embodiments, A is a hydroxyl protecting group or an amino protecting group.

[0180] In some embodiments, the hydroxyl protecting group is selected from: acyl-based hydroxyl protecting groups, ether-based hydroxyl protecting groups, acetal-based hydroxyl protecting groups, and silyl ether-based hydroxyl protecting groups, such as methyl, ethyl, benzyl (Bn), phenyl, isopropyl, tert-butyl, allyl, cyclohexyl (cHex), methoxymethyl ether (MOM), 2-tetrahydropyran (THP), tert-butyldimethylchlorosilane (TBDMSCl), TBDPS, TBDMS, 4-methoxybenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-acyloxybenzyl, 2-methylphenyl, 2,6-dimethylphenyl, 2-chlorophenyl, pyridine-2-carboxylate, benzyl ether, p-methoxybenzyl ether, triphenylmethyl ether, diphenylmethyl, 4-methylthio. -1-Butyl, 2-(S-acetylthio)ethyl (SATE), 2-cyanoethyl, 2-cyano-1,1-dimethylethyl (CDM), 4-cyano-2-butenyl, 2-(trimethylsilyl)ethyl (TSE), 2-(phenylthio)ethyl, 2-(triphenylsilyl)ethyl, 2-(benzylsulfonyl)ethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,3-dibromopropyl, 2,2,2-trifluoroethyl, phenylthio, 2-chloro-4-triphenylmethylphenyl, 2-bromophenyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 4-(N-trifluoroacetylamino)butyl, 4-oxopentyl, 4-triphenylmethylaminophenyl, 4-benzylaminophenyl.

[0181] In some embodiments, the amino protecting group is selected from: 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), tert-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz), formyl, acetyl, trihaloacetyl, benzoyl and nitrophenylacetyl, 2-nitrobenzenesulfonyl, phthalimide and dithiosuccinyl.

[0182] In some embodiments, B is an amino, hydroxyl, carboxyl, thiol, aldehyde, ketone, azide, vinyl, acryloyl, thiol ester, isocyanate, isothiocyanate, alkyl halide, sulfonyl halide, epoxide, imine ester, fluorophenyl ester, carbonate, carbodiimide, disulfide, aziridine, or a group that can undergo a coupling reaction with the above groups.

[0183] In some embodiments, B is an amino group or a group capable of undergoing a coupling reaction with an amino group.

[0184] In some embodiments, B is an amino group, an NHS ester, an imine ester, a pentafluorophenyl ester, or a hydroxymethylphosphine.

[0185] In some embodiments, B is a carboxyl group or a group capable of coupling with an amino group.

[0186] In some embodiments, B is a carboxyl group or a carbodiimide.

[0187] In some embodiments, B is a thiol group or a group capable of coupling with an amino group.

[0188] In some embodiments, B is a mercapto or maleimide, a haloacetyl group, a pyridine dimerol, a thiosulfonate, or a vinyl sulfone.

[0189] In some embodiments, B is an aldehyde group or a group capable of undergoing a coupling reaction with an aldehyde group.

[0190] In some embodiments, B is an aldehyde group, an acylhydrazine, an alkoxyamine, or an NHS ester.

[0191] In some embodiments, B is an azide or a group capable of coupling with an azide.

[0192] In some embodiments, B is an azide or a group containing an alkynyl group.

[0193] In some embodiments, B is a tetrazine or a group that can react with a tetrazine.

[0194] In some embodiments, B is tetrazine, azide, TCO, DBCO, or BCN.

[0195] In some embodiments, B is 4-formylbenzoate (4FB) or hydrazinotinamide (HyNic).

[0196] In some implementations, L is -(C(R) Xa (R) Xb )) nl -, where when X contains methylene units, each of the zero or at least one methylene unit of X is independently controlled by -N(R) Xc )C(O)-、-C(O)N(R Xc )-, -C(O)-, -OC(O)-, -C(O)O-, -NR Xc -, -O-, -S-, -SO-, -SO2-, -P(R Xc )-、-P(=O)(R Xc )-、-N(R Xc SO2-, -SO2N(R)Xc -, -C(=S)-, -C(=NR) Xc -, -N=N-, -C=N-, -N=C- or -C(=N2)- are substitutes; where each R Xa R Xb R Xc Each of these can be independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or C 1-6 An aliphatic group, wherein nl is an integer from 1 to 15. For example, nl can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, L is -(CH2). nl -, n1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

[0197] In some embodiments, the base moiety is pyrimidine, substituted pyrimidine, pseudouracil, substituted pseudouracil, purine, hypoxanthine, or substituted purine.

[0198] In some embodiments, the bases are selected from one or more of the following group:

[0199] Xanthine, allylaminouracil, allylaminothymidine, hypoxanthine, dioxane, dioxane, dioxane, dioxane, dioxane, 6-chloropurine nucleoside, N6-methyladenine, methylpseudorazine, 2-thiocytosine, 2-thiouracil, 5-methyluracil, 4-thiothymidine, 4-thiouracil, 5,6-dihydro-5-methyluracil, 5,6-dihydrouracil, 5-[(3-indolyl)propionamide-N-allyl]uracil, 5-aminoallyl cytosine, 5-aminoallyl uracil, 5-bromouracil, 5-bromocytosine, 5-carboxycytosine, 5- Carboxyuracil, 5-fluorouracil, 5-formylcytosine, 5-formylcytosine, 5-hydroxycytosine, 5-hydroxymethylcytosine, 5-hydroxymethylcytosine, 5-hydroxyuracil, 5-iodocytosine, 5-iodouracil, 5-methoxycytosine, 5-methoxyuracil, 5-methylcytosine, 5-methyluracil, 5-propynylaminocytosine, 5-propynylaminouracil, 5-propynylcytosine, 5-propynyluracil, 6-azacytosine, 6-azouridine, 6-chloropurine, 6-thioguanine, 7-deadenine, 7-deadenine, 7-deaden-7-propylaminoadenine, 7 -Denitro-7-propynylaminoadenine, 8-azaadenine, 8-azidoadenine, 8-chloroadenine, 8-oxoadenine, 8-oxoguanine, Biotin-16-aminoallylcytosine, Biotin-16-aminoallyluracil, 3-5-propynylaminocytosine, 3-6-propynylaminouracil, Cyano-3-aminoallylcytosine, Cyano-3-aminoallyllurapinidine, Cyano-5-6-propynylaminocytosine, Cyano-5-6-propynylaminouracil, Cyano-5-aminoallylcytosine, Cyano-5-aminoallyluracil, Cyano-7-aminoallyluracil, Dabcy 1-5-3-aminoallyl uracil, dethiobiotin-16-aminoallyl uracil, dethiobiotin-6-aminoallyl cytosine, isoguanine, N1-ethylpseudouracil, N1-methoxymethylpseudouracil, N1-methyladenine, N1-methylpseudouracil, N1-propylpseudouracil, N2-methylguanine, N4-biotin-OBEA-cytosine, N4-methylcytosine, N6-methyladenine, O6-methylguanine, pseudoisocytosine, pseudouracil, thienocytosine, thienoguanine, thienouracil, xanthine, 3-deadenine, 2,6-diaminoadenine, 2,6-Diaminoguanine, 5-Formamidouracil, 5-Ethynyluracil, N6-Isopentenyladenine (i6A), 2-Methylthio-N6-Isopentenyladenine (ms2i6A), 2-Methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-Methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycylcarbamoyladenine,

[0200] (g6A), N6-threonylcarbamoyladenine (t6A), 2-methylthio-N6-threonylcarbamoyladenine (ms2t6A), N6-methyl-N6-threonylcarbamoyladenine (m6t6A), N6-hydroxyvalinecarbamoyladenine (hn6A), 2-methylthio-N6-hydroxyvalinecarbamoyladenine (ms2hn6A)

[0201] N6,N6-dimethyladenine (m62A) and N6-acetyladenine (ac6A).

[0202] On the other hand, this application provides an oligonucleotide comprising the aforementioned compound. The compound may be located at the 5' end or 3' end of the oligonucleotide, or any oligonucleotide preceding the 5' end or 3' end.

[0203] On the other hand, this application provides a method for preparing target nucleic acid, comprising:

[0204] (1) Provide an extract fragment having an affinity structure, the affinity structure comprising a compound as described in formula (I), wherein functional group B is an affinity modification.

[0205] (2) A stationary phase is provided, wherein the surface of the stationary phase has a fixed modification, wherein the affinity modification and the fixed modification can be covalently or non-covalently connected.

[0206] (3) The extracted fragments were fixed onto the stationary phase by connecting affinity-modified structures and fixation-modified structures;

[0207] (4) Provide an intermediate fragment, which is ligated to the end of the extracted fragment in the presence of a ligase;

[0208] (5) Repeat step (4) until the target nucleic acid is generated;

[0209] (6) Separate the target nucleic acid from the stationary phase.

[0210] Step (2) can be provided after step (5).

[0211] On the other hand, this application provides a method for linking and purifying via a solid-phase approach, comprising:

[0212] (1) Provide one or more extractable fragments and one or more intermediate fragments, wherein the affinity structure comprises a compound as described in formula (I), wherein functional group B is affinity modified;

[0213] (2) In the presence of ligase, one or more extracted fragments and one or more intermediate fragments are ligated to form a mixture of nucleic acid fragments;

[0214] (3) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected;

[0215] (4) By linking the affinity modification and the fixation modification, the nucleic acid fragment containing the target nucleic acid in the nucleic acid fragment mixture is bound to the surface of the stationary phase;

[0216] (5) Separate the target nucleic acid from the stationary phase.

[0217] On the other hand, this application provides a method for preparing target nucleic acid, comprising:

[0218] (1) Provide an extractable fragment having an affinity structure, the affinity structure comprising a compound as described in formula (I), wherein functional group B is an affinity-modified compound.

[0219] (2) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected;

[0220] (3) The extracted fragments were fixed onto the stationary phase by connecting affinity-modified structures and fixation-modified structures;

[0221] (4) Provide an intermediate segment and connect the intermediate segment to the end of the extracted segment;

[0222] (5) Separate the target nucleic acid from the stationary phase.

[0223] A method for preparing a target nucleic acid, comprising:

[0224] (1) Provide one or more extractable fragments and one or more intermediate fragments, wherein the extractable fragments exist as an affinity structure of a compound of formula (I), wherein functional group B is an affinity modification;

[0225] (2) Connect one or more extracted fragments and one or more intermediate fragments to form a mixture of nucleic acid fragments;

[0226] (3) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected;

[0227] (4) By linking the affinity modification and the fixation modification, the nucleic acid fragment containing the target nucleic acid in the nucleic acid fragment mixture is bound to the surface of the stationary phase;

[0228] (5) Separate the target nucleic acid from the stationary phase.

[0229] In Figures 4-8, groups A' and B' represent affinity modifications (i.e., functional group B in Formula I). ​​Linker-A and linker-B can be oligonucleotides or -L- in Formula I. Cleavage sites A and B can be chemical cleavage sites (e.g., the connection between R and A in Formula I, where A leaves R) or enzyme cleavage sites.

[0230] When linker-A and linker-B are -L- in Formula I, cleavage site A and cleavage site B can be chemical cleavage sites.

[0231] When linker-A and linker-B are oligonucleotides, cleavage site A and cleavage site B can be enzyme cleavage sites.

[0232] Taking the ligation of multiple RNA oligonucleotides as an example, a group A' that can bind affinity or covalently to a solid-phase ligation medium is added to the 5' end of the first RNA segment. A universal linker-A is added between the 3' end of this group and the 5' end of the RNA oligonucleotide substrate, followed by the cleavage site A. For example, the 5' end of the first RNA segment (i.e., the extracted fragment, or the first extracted fragment) contains a structure as shown in Formula I (i.e., the affinity structure, or the first affinity structure), where -L- is the linker-A and the group A' is the functional group B (i.e., the affinity modification, or the first affinity modification).

[0233] A group B', capable of affinity or covalent binding to a solid-phase linker, is added to the 3' end of the third RNA segment. A cleavage site B and a universal linker-B are added between the 5' end of this group and the 5' end of the RNA oligonucleotide substrate. The linker-B is located at the 3' end of the cleavage site B. For example, the 5' end of the third RNA segment (i.e., the extracted fragment, or the second extracted fragment) contains a structure as shown in Formula I (i.e., an affinity structure, or a second affinity structure), where -L- represents the linker-B and the group B' represents the functional group B (i.e., an affinity modification, or a second affinity modification).

[0234] Uniparental and solid-phase linkage, amphipathic and solid-phase linkage, and covalent solid-phase linkage can be achieved through multiple RNA oligonucleotides.

[0235] First, this application provides a single-affinity solid-phase ligation method. The first RNA oligonucleotide Oligo1, containing modified groups, a linker, and a cleavage site, is affinity-bound to a solid-phase medium A. An excess of RNA oligonucleotide is used to ensure that all affinity groups on the surface of solid-phase medium A are aggregated by the RNA oligonucleotide. Then, enzymatic ligation is performed on the second RNA oligonucleotide Oligo2 on the solid-phase medium. After ligation, the oligonucleotides are thoroughly washed with a washing buffer. Unligated residual oligonucleotides are then subjected to solid-phase ligation and purification again to obtain the target ligation product. Finally, the DNA adapter used in the ligation process is digested with DNase I to obtain long-chain RNA (as shown in Figure 4).

[0236] The single-phase ligation method increases the sequence length by continuously adding intermediate fragments (zigzag fragments) to be extended through enzymatic ligation. It is crucial to ensure an excess of substrate at each step for maximum ligation efficiency, thus maximizing the yield of the target sequence product on the solid-phase vector. Furthermore, because each sequence is unique, the interface is affected by sequence specificity, preventing non-specific ligation and maximizing accuracy and yield.

[0237] Furthermore, this application provides an amphiphilic and solid-phase ligation method for enzymatically ligating the aforementioned first RNA oligonucleotides Oligo1, Oligo2, and Oligo3, which have modified groups, linker, and cleavage sites. The ligation product is a mixture of multiple products, including the remaining substrate, Oligo1, Oligo2, and Oligo3, unreacted byproducts Oligo1-Oligo2 and Oligo2-Oligo3, and the target product Oligo1-Oligo2-Oligo3.

[0238] The ligation product binds to solid-phase medium A via the 5' end modification group A' of Oligo1. Impurities Oligo2, Oligo3, and Oligo2-Oligo3 are removed by purification through solid-phase medium A. The universal linker-A is cleaved using enzymatic or chemical methods, and the purified product is eluted. The product is then further purified by affinity purification via the 3' end modification group B' of Oligo3 and solid-phase medium B to remove impurities Oligo1 and Oligo1-Oligo2. The universal linker-B is cleaved using enzymatic or chemical methods, and the purified product is eluted. The DNA adapter is then digested with DNase I to obtain long RNA. (See Figure 5)

[0239] Amphiphilic and solid-phase linkage methods effectively reduce byproduct residues, ensuring maximum cleaning of byproducts that are not specifically linked at each step, resulting in the highest specificity and purity.

[0240] Multiple rounds of affinity solid-phase ligation can further ligate the products from a single affinity ligation, followed by column-based ligation to form longer chains. This process can be repeated indefinitely to obtain infinitely long products. As shown in Figure 6, the product from the first round of solid-phase affinity ligation is eluted without removing the linker, and the Oligo2, Oligo3, and Oligo2-Oligo3 byproducts are removed. Affinity purification using solid-phase medium B yields a ligation product with modifying group A', linker-A, and cleavage site A. Further solid-phase ligation purification with the ligation product containing modifying group B', linker-B, and cleavage site B yields an even longer ligation product, as shown in Figure 6.

[0241] The connection method between the modifying group and the binding medium can be changed to covalent bonding, as shown in Figure 7. The target ligation product and byproducts with modification A' are covalently linked to solid-phase medium A. After ligation, various denaturation methods can be used for washing to further improve purity. Other purification and cleavage methods are consistent with the amphiphilic solid-phase ligation method. The ligation product is covalently bound to solid-phase medium A via the 5' end modification group A' of Oligo1. Impurities Oligo2, Oligo3, and Oligo2-Oligo3 are removed through solid-phase purification. The universal linker-A is cleaved by enzymatic or chemical methods, and the purified product is eluted. The product is then further purified by affinity purification using the 3' end modification group B' of Oligo3 and solid-phase medium B to remove impurities Oligo1 and Oligo1-Oligo2. The universal linker-B is cleaved by enzymatic or chemical methods, and the purified product is eluted. The DNA adapter is then digested with DNase I to obtain long RNA.

[0242] The final RNA product obtained from the first round of solid-phase covalent ligation purification can be further processed by enzymatic ligation to add linkers with modified groups at the 5' and 3' ends. As shown in Figure 8, the ligation product of Oligo1-2-3 is treated with T4PNK to add P modification to the 5' end of Oligo1-2-3. Then, linker-A with modified group A' is ligated to the 5' end of Oligo1-2-3 using T4 RNA ligase1. At the same time, Oligo4-5-6 is treated with T4PNK to add P modification to its 5' end. The third ligation product is first ligated with linker-B with modified group B' to the 3' end of Oligo7-8-9 using T4 RNA ligase1, and then treated with T4PNK to add P modification to its 5' end. After pretreatment, an adapter paired with Oligo is added for enzymatic ligation. The subsequent covalent ligation and purification methods are the same as those for solid-phase covalent ligation purification. Multiple rounds of solid-phase ligation can link the purified product from a single step to the 5' or 3' end of the product via enzymatic ligation. Repeating the solid-phase ligation purification process can form longer chains and can be repeated indefinitely to obtain infinitely long products.

[0243] On the one hand, this application provides a method for preparing a target nucleic acid, comprising: (1) providing an extraction fragment, wherein the 5' end or 3' end of the extraction fragment has an affinity structure, and the affinity structure has an affinity modification; (2) providing a stationary phase, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently linked; (3) fixing the extraction fragment onto the stationary phase through the affinity modification structure and the fixation modification structure; (4) providing an intermediate fragment, and in the presence of a ligase, ligating the intermediate fragment to the end of the extraction fragment; (5) repeating step (4) until the target nucleic acid is generated; and (6) separating the target nucleic acid from the stationary phase.

[0244] In some embodiments, the affinity structure further includes an enzymatically cleavable site, wherein the affinity modification is linked to the extracted fragment via the enzymatically cleavable site.

[0245] On the one hand, this application provides a method for preparing a target nucleic acid, comprising: (1) providing one or more extract fragments and one or more intermediate fragments, wherein the 5' end or 3' end of the extract fragment has an affinity structure, the affinity structure including an affinity modification; (2) in the presence of a ligase, connecting the one or more extract fragments and one or more intermediate fragments to form a nucleic acid fragment mixture; (3) providing a stationary phase, wherein the surface of the stationary phase has a stationary modification, wherein the affinity modification and the stationary modification can be covalently or non-covalently linked; (4) binding the nucleic acid fragment containing the target nucleic acid in the nucleic acid fragment mixture to the surface of the stationary phase through the linking of the affinity modification and the stationary modification; and (5) separating the target nucleic acid from the stationary phase.

[0246] In some embodiments, the extracted fragments include a first extracted fragment and a second extracted fragment. The first extracted fragment includes a first affinity structure, which includes a first affinity modification. The second extracted fragment includes a second affinity structure, which includes a second affinity modification. The first affinity modification and the second affinity modification are different.

[0247] In some embodiments, the first extractable fragment further includes a first cleavable site, wherein a first affinity modification is linked to the first extractable fragment via the first cleavable site, and the second extractable fragment further includes a second cleavable site, wherein a second affinity modification is linked to the second extractable fragment via the second cleavable site, and step (5) involves separating the target nucleic acid on a stationary phase via the cleavage site. In some embodiments, the first cleavable site and the second cleavable site are different.

[0248] In some embodiments, the stationary phase includes a first stationary phase and a second stationary phase. The first stationary phase includes a first stationary modification, wherein the first affinity modification and the first stationary modification can be covalently or non-covalently connected. The second stationary phase includes a second stationary modification, wherein the second affinity modification and the second stationary modification can be covalently or non-covalently connected.

[0249] In some embodiments, the method further includes (1) purifying the nucleic acid fragment mixture by passing it through a first stationary phase to remove non-specifically binding impurities and cleaving it at a first cleavable site to obtain a first mixture; and (2) purifying the first mixture by passing it through a second stationary phase to remove non-specifically binding impurities and cleaving it at a second cleavable site to separate the target nucleic acid from the second stationary phase.

[0250] In some embodiments, the extracted fragment and / or intermediate fragment is a single-stranded nucleic acid fragment or a double-stranded nucleic acid fragment.

[0251] In some embodiments, the extracted fragment and / or intermediate fragment is a single-stranded DNA fragment or an RNA fragment.

[0252] In some embodiments, the extracted fragment and / or intermediate fragment is a DNA double-stranded fragment, an RNA double-stranded fragment, or an RNA / DNA hybrid fragment.

[0253] In some embodiments, one or both ends of the extracted fragment and / or intermediate fragment have a protruding structure, wherein the length of the protruding structure is 2-200 nt.

[0254] The single-stranded RNA preparation method described in this application includes an RNA fragment designed based on the target single-stranded RNA, a corresponding DNA fragment hybridized with the RNA fragment, and an RNA / DNA hybrid double-stranded fragment.

[0255] There can be N types of RNA fragments designed based on the target single-stranded RNA, and the N RNA fragments can be linked to form a complete target single-stranded RNA. N can be any integer greater than or equal to 2. For example, N can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. That is, there can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 types of RNA fragments designed based on the target single-stranded RNA.

[0256] Correspondingly, the number of DNA fragments and RNA / DNA hybrid double-stranded fragments that hybridize with the RNA fragments is the same as the number of RNA fragments, and can also be N. Each of the N DNA fragments can correspond one-to-one with one of the N RNA fragments, forming N types of RNA / DNA hybrid double-stranded fragments. N can be any integer greater than or equal to 2. For example, N can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. That is, there can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 types of DNA fragments, and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 types of RNA / DNA hybrid double-stranded fragments.

[0257] The ends of the RNA fragment, DNA fragment, and / or RNA / DNA hybrid double-stranded fragment may have modifying groups. These modifying groups may include hydroxyl, phosphate, amino, and any other modifying groups. The phosphate group modification may be a phosphate modification or a thiophosphate modification.

[0258] The 3' end of the RNA fragment may be modified with a hydroxyl group or a phosphate group.

[0259] The 5' end of the RNA fragment may be modified with a hydroxyl group or a phosphate group.

[0260] In some embodiments, the DNA fragment is either unmodified or has hydroxyl-modified ends.

[0261] In some embodiments, the 5' end and / or 3' end of the DNA includes amino modifications.

[0262] When two adjacent RNA fragments, i.e., the 3' end of the first RNA fragment and the 5' end of the second RNA fragment, can be joined to form a continuous portion of the target single-stranded RNA, if the 3' end of the first RNA fragment is modified with a phosphate group, then the 5' end of the second RNA fragment is modified with a hydroxyl group. Conversely, if the 3' end of the first RNA fragment is modified with a hydroxyl group, then the 5' end of the second RNA fragment is modified with a phosphate group.

[0263] For two adjacent RNA / DNA hybrid double-stranded fragments, namely RNA / DNA hybrid double-stranded fragment 1 and its adjacent RNA / DNA hybrid double-stranded fragment 2 (where the 3' end of the RNA fragment of RNA / DNA hybrid double-stranded fragment 1 and the 5' end of the RNA fragment of RNA / DNA hybrid double-stranded fragment 2 are joined to form a continuous portion of the target single-stranded RNA), the modification rules are as follows:

[0264] If the 3' end of the RNA fragment of hybrid double-stranded fragment 1 is modified with a phosphate group, then the 5' end of the RNA fragment of hybrid double-stranded fragment 2 is modified with a hydroxyl group; or,

[0265] If the 3' end of the RNA fragment of hybrid double-stranded fragment 1 is modified with a hydroxyl group, then the 5' end of hybrid double-stranded fragment 2 is modified with a phosphate group.

[0266] The purpose is to ensure that the RNA in two adjacent RNA / DNA hybrid double-stranded fragments can bind under the action of ligase.

[0267] The plurality of RNA / DNA hybrid double-stranded fragments may include a 5' end fragment and / or a 3' end fragment. The plurality of RNA / DNA hybrid double-stranded fragments include a 5' end fragment and / or a 3' end fragment, wherein the 5' end of the RNA fragment in the 5' end fragment is blunt, and the 3' end of the RNA fragment in the 3' end fragment is blunt.

[0268] In other words, for RNA / DNA hybrid double-stranded fragments, taking the 3' and 5' ends of the RNA as references, the RNA / DNA hybrid double-stranded fragment can have a blunt end at the 3' end and a sticky end at the 5' end (this may occur when the RNA is the 3' end of the target single-stranded RNA); the RNA / DNA hybrid double-stranded fragment can have a blunt end at the 5' end and a sticky end at the 3' end (this may occur when the RNA is the 5' end of the target single-stranded RNA); the RNA / DNA hybrid double-stranded fragment can have a sticky end at both the 3' and 5' ends (this may occur when the RNA is the 5' end of the target single-stranded RNA).

[0269] The length of the RNA fragment can be 20-1000 nt.

[0270] The length of the RNA fragment can be 20-1500 nt. The length of the RNA fragment can be 20-1000 nt. The length of the RNA fragment can be 20-500 nt.

[0271] The length of the RNA fragment can be 20-100, 20-99, 20-98, 20-97, 20-96, 20-95, 20-94, 20-93, 20-92, 20-91, 20-90, 20-89, 20-88, 20-87, 20-86, 20-85, 20-84, 20-83, 20-82, 20-81, 20-80, 20-79, 20-78, 20-77, 20-76, 20-75, 20-74, 20-73, 20-72, 20-71, 20-70, 20-69, 20-68, 20-67, 20-66, 20-65, 20-64, 20-63, 20-62. 20-61, 20-60, 20-59, 20-58, 20-57, 20-56, 20-55, 2-54, 20-53, 20-52, 20-51, 20-50, 20-49, 20-48, 20-47, 20-46, 20-45, 2-44, 20-43, 20-42, 20-41, 20-40, 20-39, 20-38, 20-37, 20-36, 20-35, 2-34, 20-33, 20-32, 20-31, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 2-24, 20-23, 20-22 or 20-21nt.

[0272] The RNA / DNA hybrid double-stranded fragment has overhangs at one or both ends. When both ends of the RNA / DNA hybrid double-stranded fragment have overhangs, the lengths of the overhangs can be the same. When both ends of the RNA / DNA hybrid double-stranded fragment have overhangs, the lengths of the overhangs can be different. When both ends of the RNA / DNA hybrid double-stranded fragment have overhangs, the sequences of the two overhangs can be inversely complementary.

[0273] The length of the protruding structure can be 6-20 nt.

[0274] The length of the protruding structure can be 6-7, 6-8, 6-9, 6-10, 6-11, 6-12, 6-13, 6-14, 6-15, 6-16, 6-17, 6-18, 6-19, or 6-20 nt. The length of the protruding structure can be 7-8, 7-9, 7-10, 7-11, 7-12, 7-13, 7-14, 7-15, 7-16, 7-17, 7-18, 7-19, or 7-20 nt. The length of the protruding structure can be 8-9, 8-10, 8-11, 8-12, 8-13, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, or 8-20 nt. The length of the protruding structure can be 9-10, 9-11, 9-12, 9-13, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, or 9-20 nt. The length of the protruding structure can be 10-11, 10-12, 10-13, 10-14, 10-15, 10-16, 10-17, 10-18, 10-19, or 10-20 nt. The length of the protruding structure can be 11-12, 11-13, 11-14, 11-15, 11-16, 11-17, 11-18, 11-19, or 11-20 nt. The length of the protruding structure can be 12-13, 12-14, 12-15, 12-16, 12-17, 12-18, 12-19, or 12-20 nt. The length of the protruding structure can be 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, or 13-20 nt. The length of the protruding structure can be 14-15, 14-16, 14-17, 14-18, 14-19, or 14-20 nt. The length of the protruding structure can be 15-16, 15-17, 15-18, 15-19, or 15-20 nt. The length of the protruding structure can be 16-17, 16-18, 16-19, or 16-20 nt. The length of the protruding structure can be 17-18, 17-19, or 17-20 nt. The length of the protruding structure can be 18-19 or 18-20 nt. The length of the protruding structure can be 19-20 nt.

[0275] Excessively long protrusions can lead to secondary structures in DNA / RNA hybridization double-stranded fragments. Therefore, the length of protrusions should not exceed 20 nt, 19 nt, 18 nt, 17 nt, or 16 nt.

[0276] At the same time, excessively short protrusions may lead to reduced connection efficiency. Therefore, the length of the protrusion should be no less than 2nt, no less than 3nt, or no less than 4nt.

[0277] The length of the protruding structure can be 4-16 nt.

[0278] The prominent structure is a free-floating structure with no strong secondary structure.

[0279] In some embodiments, the affinity modification and the fixation modification can be covalently linked.

[0280] In some embodiments, the covalent connection forms a linker, which includes amino-reactive linkers, carboxyl-amino-reactive linkers, thiol-reactive linkers, aldehyde-reactive linkers, photoreactive linkers, or azide-reactive linkers.

[0281] In some embodiments, the linker is an amino-reactive linker, including NHS esters, imine esters, pentafluorophenyl esters, or hydroxymethylphosphine. For example, the affinity modification is amino, and the immobilization modification is NHS ester, imine ester, pentafluorophenyl ester, or hydroxymethylphosphine. Yet another example is that the immobilization modification is amino, and the affinity modification is NHS ester, imine ester, pentafluorophenyl ester, or hydroxymethylphosphine.

[0282] In some embodiments, the linker is a thiol-reactive linker, including maleimide, haloacetyl (bromo-, chloro-, or iodine-), pyridine dimercapto, thiosulfonate, and vinyl sulfone. For example, the affinity modification is a thiol group, and the fixation modification is one of maleimide, haloacetyl (bromo-, chloro-, or iodine-), pyridine dimercapto, thiosulfonate, and vinyl sulfone. Alternatively, the fixation modification is a thiol group, and the affinity modification is one of maleimide, haloacetyl (bromo-, chloro-, or iodine-), pyridine dimercapto, thiosulfonate, and vinyl sulfone.

[0283] In some embodiments, the linker is an aldehyde-reactive linker, including acylhydrazides, alkoxyamines, and NHS esters. For example, the affinity modification is an aldehyde group, and the immobilization modification is an acylhydrazide, alkoxyamine, or NHS ester. Alternatively, the immobilization modification is an aldehyde group, and the affinity modification is an acylhydrazide, alkoxyamine, or NHS ester.

[0284] In some embodiments, the linker is a click chemistry linker.

[0285] In some embodiments, the affinity structure at the 5' or 3' end of the extracted fragment is located on the 2nd carbon of the 5' or 3' end nucleotide.

[0286] In some embodiments, the compound is located at the 5' end or 3' end of the polynucleotide, or between the 5' end and 3' end.

[0287] In some embodiments, the affinity structure includes an acetal structure or a silane structure.

[0288] In some embodiments, the affinity structure includes one of the following:

[0289] Where Ra is a part of a ribonucleotide or deoxyribonucleotide, for example, Ra can be C, O or P. Rc is the stationary phase, and Rb is -(C(Raa)(Rab))na, wherein when Rb contains methylene units, the zero or at least one methylene unit of Rb is independently converted by -N(Raaa)C(O)-, -C(O)N(Raaa)-, -C(O)-, -OC(O)-, -C(O)O-,

[0290] -NRaaa-, -O-, -S-, -SO-, -SO2-, -P(Raaa)-, -P(=O)(Raaa)-, -N(Raaa)SO2-, -SO2N(Raaa)-,

[0291] -C(=S)-, -C(=NRaaa)-, -N=N-, -C=N-, -N=C- or -C(=N2)- can be substituted;

[0292] Each of Raa, Rab, Racc, and Raaa is independently represented by hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, or -OH.

[0293] -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2,

[0294] -SO2NH2, -OC(O)H, -N(H)SO2H, or C1-6 aliphatic groups;

[0295] na is an integer that is at least 1. For example, na can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, etc.

[0296] In some embodiments, the modification of the affinity structure may include the following: 2' modification of the monomer, 5' modification of the monomer, 3' modification of the monomer, or modification of the monomer by a radical.

[0297] 2' modification refers to the -ALB structure being attached to the 2' hydroxyl position of a deoxyribonucleotide or ribonucleotide. Because -A- is essentially a hydroxyl protecting group, the -ALB structure can bind to the 2' hydroxyl group and leave under certain conditions. For example, the compounds described in this application include a structure in which the phosphate group can be attached to a hydrogen atom or other nucleotide, and the phosphate group can be replaced with thiophosphate or a phosphorus-containing reactive group.

[0298] Where n is 1, 2, 3, 4, 5, 6, 7 or 8, and R2 is a hydroxyl group or The base portion has one of the following -B structures:

[0299] (CH2) m SS-, -SH, -NH2, -COOH

[0300] Where m is an integer from 1 to 10, for example, m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0301] 5' modification refers to the -ALB structure being attached to the 5' hydroxyl position of a deoxyribonucleotide or ribonucleotide. Because -A- is essentially a hydroxyl protecting group, the -ALB structure can bind to the 5' hydroxyl group and leave under certain conditions. For example, the compounds described in this application include a structure in which the phosphate group can be attached to hydrogen or other nucleotides, and the phosphate group can be replaced with thiophosphate or a phosphorus-containing reactive group:

[0302] Where n is an integer from 1 to 15, for example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and R2 is a hydroxyl group or

[0303] The base is the base moiety, X2 is hydrogen, halogen (e.g., fluorine), hydroxyl, or methoxy, and the -B structure is one of the following:

[0304] (CH2) m SS-, -SH, -NH2, -COOH

[0305] Where m is an integer from 1 to 10, for example, m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0306] 3' modification refers to the -ALB structure being attached to the 3' hydroxyl position or phosphate group of a deoxyribonucleotide or ribonucleotide. Because -A- is essentially a hydroxyl protecting group, the -ALB structure can bind to the 3' hydroxyl group or phosphate group and leave under certain conditions. For example, the compounds described in this application include one of the following structures:

[0307] Where n is an integer from 1 to 15, for example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and R2 is a hydroxyl group or The base is the base moiety, and X2 is hydrogen, halogen (e.g., chlorine or fluorine), hydroxyl or methoxy. The stationary phase is, for example, PS or CPS. The stationary phase has a fixed modification that can undergo a coupling reaction with the -B modification. X1 is the group formed after the fixed modification reacts with the -B group, and the -B structure is one of the following:

[0308] (CH2) m SS-, -SH, -NH2, -COOH

[0309] Where m is an integer from 1 to 10, for example, m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0310] In some embodiments, the affinity modification and fixation modification can be covalently or non-covalently linked.

[0311] In some embodiments, the Kd value of the non-covalent connection is less than 1E-5.

[0312] In some embodiments, the non-covalent linkages are biotin and streptavidin linkages, 6xHis linkages with nickel / cobalt / copper / zinc media, GST linkages with glutathione media, MBP linkages with amylose media, CBP linkages with calcium media, CBD linkages with chitin media, and Halo tag linkages with halogen media.

[0313] In some implementations, the non-covalent link is the linking of protein A and / or protein G to the antibody.

[0314] In some embodiments, the cleavable site can be cleaved by a restriction endonuclease.

[0315] In some embodiments, the endonucleases include Type I, Type II, Type III, Type IV, Type V or Type VIII, Endonuclease V, Endonuclease Q, Authenticase, USER, USER I, USER II, USER III, and FEN1.

[0316] In some embodiments, the ligase includes RNA ligase and / or DNA ligase.

[0317] In some embodiments, the ligase includes T4 DNA ligase, T4 RNA ligase 1, T4 RNA ligase 2, T3 DNA ligase, T7 DNA ligase, eukaryotic DNA ligase I, eukaryotic DNA ligase III, eukaryotic DNA ligase IV, E. coli DNA ligase, and Hi-T4. TM DNA ligase, Salt-T4 DNA ligase, 9°N TM DNA ligase, Taq DNA ligase, HiFi Taq DNA ligase One or more of the following: ligase, thermostable 5' App DNA / RNA ligase, RtcB ligase, and PBCV DNA ligase.

[0318] In some embodiments, the length of the extracted fragment and / or intermediate fragment is 20-10000 nt.

[0319] Without being limited by any theory, the embodiments described below are merely for illustrating the various technical solutions of the present invention and are not intended to limit the scope of the present invention.

[0320] Example

[0321] Example 1: Synthesis of single-parent and purification mode 2' modification:

[0322] In the following examples, Oligo can represent a nucleotide or oligonucleotide fragment, or it can be hydrogen.

[0323] (1) Synthesis of 2'THP-TCO-rU-phosphoramidite (THP-TCO monomer)

[0324] Synthetic route

[0325] Synthetic route: Step 1: cis-TCO is irradiated with UV (254 nm) to generate trans-TCO, which then reacts with DSC ester to generate trans-TCO-NHS (1c); Step 2: 2-hydroxymethyl-3,4-dihydropyran DSC ester reacts to generate pyran-NHS (2b); Step 3: uracil nucleoside and TIPSCl2 react in an alkaline environment to generate a silyl ether protected nucleoside compound (I); Step 4: intermediates (I) and (2b) undergo an addition reaction catalyzed by TsOH to generate intermediate (II), which then reacts directly with hexamethylenediamine without purification to generate... Intermediate state (III); in the fifth step, intermediate state (III) reacts with trans-TCO-NHS to generate intermediate state (IV); in the sixth step, intermediate state (IV) undergoes desilane protection under the action of Et3N·HF to generate intermediate state (V); in the seventh step, intermediate state (V) reacts with DMTr-Cl to generate intermediate state (VI); in the eighth step, intermediate state (VI) undergoes the action of tetrazolium and bis(diisopropylamino)(2-cyanoethoxy)phosphine to generate the final phosphoramidite monomer V (i.e., 5'-DMT-2'-THP-TCO-U-Phosphoramidite).

[0326] The NMR-H spectrum is shown in Figure 1A, and the NMR-P spectrum is shown in Figure 1B.

[0327] (2) Synthesis of 2'THP-SS-rU-phosphoramidite (THP-SS monomer)

[0328] Synthetic route

[0329] Synthetic route: First, 1-hexathiol (Q1) and 6-mercaptohex-1-ol (Q2) are reacted with iodine to generate a disulfide compound (CL1) with a hydroxyl group. Second, Ts-Cl reacts with the hydroxyl group of CL1 to generate an active ester (CL2). Third, CL2 and 2-hydroxymethyl-3,4-dihydropyran (Q6) react under the influence of HNa after dehydrogenation and substitution to generate compound CL. Fourth, uracil nucleoside (Q3) and TIPSCl2 (Q4) react in an alkaline environment to generate a silyl ether-protected nucleoside compound I. In step five, compound I and CL undergo an addition reaction catalyzed by TsOH to generate compound II; in step six, compound II undergoes a desilylation reaction under the action of HF / TEA to generate compound III; in step seven, compound III reacts with DMT-Cl to generate compound IV with DMT protection at the 5' end; in step eight, compound IV reacts with tetrazolium and bis(diisopropylamino)(2-cyanoethoxy)phosphine to generate the final phosphoramidite monomer V (i.e., 5'-DMT-2'-THP-SSU-Phosphoramidite).

[0330] Nuclear magnetic resonance (NMR) quality control characterization: NMR-H spectrum is shown in Figure 1C, and NMR-P spectrum is shown in Figure 1D.

[0331] Single-parent and purification process flow:

[0332] Preparation of Tz-media and SH-Py-media:

[0333] Tz-media preparation: Tetrazine-Ph-opss raw material was dissolved in DMSO, and then incubated overnight at 37°C with 0.1M PB (pH=8.0) at a reaction ratio of 2:1 with mercapto-agarose medium. After the reaction, the medium was first washed with water for 10 min, then with DMSO for 10 min, then with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0334] Preparation of SH-Py-media: The thiol media was prepared into a 50% ethanol solution containing 1 mM EDTA in 0.1 M Tris-HCl pH 8.0, and reacted overnight at 37°C under conditions containing 30 mg / ml dithiopyridine. After the reaction, the media was first washed with water for 10 min, then washed with anhydrous ethanol for 20 min, followed by washing with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0335] Step 1: Media bonding (THP-TCO monomers use Tz-media, THP-SS monomers use SH-Py-media)

[0336] The sample to be attached to the column was thoroughly mixed with the medium under 0.1M PB (pH=8.0) conditions, and then incubated at 37℃ for 1h to bind.

[0337] Step 2: Cleaning

[0338] After the combined medium liquid was extracted, it was washed with 8M GuHCl + 5mM PB (pH=8.0) + 1mM EDTA (pH=8.0) solution for 30 minutes by filtration. Then the medium was replaced 3 times with 0.1M NaHCO3 solution.

[0339] Step 3: Restore

[0340] The cleaned media was incubated in 0.1M DTT + 0.1M NaHCO3 solution at 37°C for 1 hour. The reducing solution was collected, and then washed with 0.1M DTT + 0.1M NaHCO3 solution for 3 times the volume of the media before combining them together.

[0341] Step 4: Desalination + Testing

[0342] The collected reducing solution was desalted using a hydroxyl column, and then its purity was determined by PAGE electrophoresis.

[0343] The results of single-parent and purified PAGE purity assays are shown in Figure 1E. The synthesized and purified sequences are shown below:

[0344] 20nt RNA:U(THP-SS)AAAAUAAGGCUAGUCCGUU

[0345] 23nt-antisense strand:U(THP-SS):mA*fC*mAfAfAfAmGfCmAfAmAfAmCfAmGfGmUfCmUmAmG*mA*mA

[0346] 40nt-RNA:U(THP-SS)AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0347] 50nt-RNA:U(THP-SS)AAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAGUGGCACCGAGUCGGU

[0348] 60ntDTM-TCO:U(THP-TCO)AGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUUUU

[0349] 80ntDTM-TCO:U(THP-TCO)UUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGGCUUUU

[0350] 100ntDTM-TCO:U(THP-TCO)GCGAGCACAGCUAAGGCCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUUUU.

[0351] As shown in the figure, using a single-parent purification method can improve the purification effect.

[0352] Example 2: Single Affection Mode Two: Modification of the 5' End

[0353] 5'DTM-TCO-rU-phosphoramidite

[0354] Synthetic route

[0355] Synthetic route: First, methyl α-bromoisobutyrate reacts with thiourea, followed by alkali and acid treatment to obtain α-mercaptoisobutyric acid (CL4). Then, DPD is used to protect the thiol group, generating Py-protected mercaptoisobutyric acid (CL3). Second, hexamethylenediamine reacts with (Boc)₂O to generate a mono-Boc-protected intermediate (CL2). Third, CL3 and CL2 undergo an amide condensation reaction, followed by DTT removal of the Py protecting group to generate the intermediate (CL). Fourth, uridine protected by methylation at position 2 and DTMr at position 5 undergoes a two-step reaction involving TBS at position 3 and DTMr removal at position 5 to generate the intermediate. II); In the fifth step, intermediate (II) reacts with DMSO and acetic anhydride to generate intermediate (III); In the sixth step, intermediate (III) reacts with sulfonyl chloride and potassium p-toluenethiosulfonate to generate transition state (IV), which then reacts with CL to generate intermediate (V); In the seventh step, intermediate (V) undergoes desilane treatment and reacts with trans-TCO-NHS to generate intermediate (VII); In the eighth step, intermediate (VII) reacts with chlorophosphorus reagent under the action of a weak base DIEA to generate the final phosphoramidite monomer VIII (i.e., 5'-DTM-TCO-2'-OMe-U-Phosphoramidite).

[0356] Nuclear magnetic resonance (NMR) quality control characterization: NMR-H spectrum is shown in Figure 2A, and NMR-P spectrum is shown in Figure 2B.

[0357] Single-parent and purification process flow:

[0358] Preparation of Tz-media and SH-Py-media:

[0359] Tz-media preparation: Tetrazine-Ph-opss raw material was dissolved in DMSO, and then incubated overnight at 37°C with 0.1M PB (pH=8.0) at a reaction ratio of 2:1 with mercapto-agarose medium. After the reaction, the medium was first washed with water for 10 min, then washed with DMSO for 10 min, then washed with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0360] Preparation of SH-Py-media: The thiol media was prepared into a 50% ethanol solution containing 1 mM EDTA in 0.1 M Tris-HCl pH 8.0, and reacted overnight at 37°C under conditions containing 30 mg / ml dithiopyridine. After the reaction, the media was first washed with water for 10 min, then washed with anhydrous ethanol for 20 min, followed by washing with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0361] Step 1: Media bonding (DTM-TCO monomers use Tz-media)

[0362] The sample to be attached to the column was thoroughly mixed with the medium under 0.1M PB (pH=8.0) conditions, and then incubated at 37℃ for 1h to bind.

[0363] Step 2: Cleaning

[0364] After the combined medium liquid was extracted, it was washed with 8M GuHCl + 5mM PB (pH=8.0) + 1mM EDTA (pH=8.0) solution for 30 minutes by filtration. Then the medium was replaced 3 times with 0.1M NaHCO3 solution.

[0365] Step 3: Restore

[0366] The cleaned media was incubated in 0.1M DTT + 0.1M NaHCO3 solution at 37°C for 1 hour. The reducing solution was collected, and then washed with 0.1M DTT + 0.1M NaHCO3 solution for 3 times the volume of the media before combining them together.

[0367] Step 4: Desalination + Testing

[0368] The collected reducing solution was desalted using a hydroxyl column, and then its purity was determined by PAGE electrophoresis. The results are shown in the figure.

[0369] The results of single-parent and purified PAGE purity assays are shown in Figure 2C. The synthesized and purified sequences are shown below:

[0370] 60ntDTM-TCO:mU(DTM-TCO)AGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUUUU

[0371] 80ntDTM-TCO:mU(DTM-TCO)UUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGGCUUUU

[0372] 100ntDTM-TCO:mU(DTM-TCO)GCGAGCACAGCUAAGGCCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGGCUUUU

[0373] As shown in the figure, using a single-parent purification method can improve the purification effect.

[0374] Example 3: Biparental Purification Mode:

[0375] The oligonucleotide synthesized in this embodiment has a 5' end of THP-TCO and a 3' end of THP-SS.

[0376] Parent-child process flow:

[0377] Preparation of Tz-media and SH-Py-media:

[0378] Tz-media preparation: Tetrazine-Ph-opss raw material was dissolved in DMSO, and then incubated overnight at 37°C with 0.1M PBS (pH=8.0) at a reaction ratio of 2:1 with mercapto-agarose medium. After the reaction, the medium was first washed with water for 10 min, then with DMSO for 10 min, then with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0379] Preparation of SH-Py-media: The thiol media was prepared into a 50% ethanol solution containing 1 mM EDTA in 0.1 M Tris-HCl pH 8.0, and reacted overnight at 37°C under conditions containing 30 mg / ml dithiopyridine. After the reaction, the media was first washed with water for 10 min, then washed with anhydrous ethanol for 20 min, followed by washing with 20% ethanol, and finally stored in 20% ethanol at 4°C.

[0380] Parents and purification:

[0381] Enzymatic splicing: T4 RNA ligase 2 combines single-stranded RNA fragments with phosphate-modified 5' ends and single-stranded RNA fragments with hydroxyl-modified 3' ends at the interface through base complementarity, as shown in Figure 3A.

[0382] The connection system is as follows:

[0383] After preparing the mixture according to the above system, place it in a constant temperature metal bath and incubate at 25°C for 1 hour to complete the enzymatic splicing. The key is to ensure that the 5' end of the enzyme ligation product is modified with THP-TCO monomer and the 3' end is modified with THP-SS monomer;

[0384] Step 1: First step of medium bonding

[0385] The sample to be attached to the column was thoroughly mixed with the medium under 0.1M PB (pH=8.0) conditions, and then incubated at 37℃ for 1h to bind.

[0386] Step 2: Cleaning

[0387] After the combined medium liquid was extracted, 20 column volumes were washed with 0.1M PB (pH=8.0) + 10% acetonitrile, 20 column volumes were washed with 8M GuHCl + 5mM PB (pH=8.0) + 1mM EDTA (pH=8.0), and 3 column volumes were washed with 0.1M NaHCO3.

[0388] Step 3: Restore

[0389] The cleaned media was incubated in 0.1M DTT + 0.1M NaHCO3 solution at 37°C for 1 hour. The reducing solution was collected, and then washed with 0.1M DTT + 0.1M NaHCO3 solution for 3 times the volume of the media before combining them together.

[0390] Step 4: Desalination + Testing

[0391] The collected reducing solution was desalted using a hydroxyl column, and then its purity was determined by PAGE electrophoresis.

[0392] Step 5: NEM sealing

[0393] The enzyme-linked product was added to NEM at a molar volume of 20 times and the first-step affinity product and incubated for 1 h at 0.1 M PB (pH = 7.0) for blocking, followed by desalting with a hydroxyl column.

[0394] Step Six: Second Step - Medium Bonding

[0395] The sample to be attached to the column was thoroughly mixed with the medium under 0.1M PB (pH=8.0) conditions, and then incubated at 37℃ for 1h to bind.

[0396] Step 7: Cleaning

[0397] After the bound medium liquid was removed, 20 column volumes were washed with 0.1M PB (pH=8.0) + 10% acetonitrile, 20 column volumes were washed with 8M GuHCl + 5mM PB (pH=8.0) + 1mM EDTA (pH=8.0), and 3 column volumes were washed with 0.1M NaHCO3.

[0398] Step 8: Restore

[0399] The cleaned media was incubated in 0.1M DTT + 0.1M NaHCO3 solution at 37°C for 1 hour. The reducing solution was collected, and then washed with 0.1M DTT + 0.1M NaHCO3 solution for 3 times the volume of the media before combining them together.

[0400] Step Nine: Desalination + Testing

[0401] The collected reducing solution was desalted using a hydroxyl column, and then its purity was determined by gel electrophoresis, which is the HPLC-like purity result shown in the PAGE graph below.

[0402] To further improve the purity of the amphiphilic and purified product, more refined purification can be performed using RP-HPLC, resulting in a final pure product with HPLC-plus purity.

[0403] The experimental steps for developing the reverse-phase purification method are as follows:

[0404] Table 1. Basic Information on Reverse-Phase Purification

[0405] Preparation of mobile phase for ion purification:

[0406] Buffer A (reverse phase): 100mM TEAB + 4M urea in H2O (pH 7.0)

[0407] Preparation of 2M TEAB stock solution: Taking the preparation of 500mL 2M TEAB system as an example, accurately measure 139.19mL of triethylamine, add ultrapure water to make up to 500mL, shake to mix well, and then charge CO2 into the solution until the pH reaches 7.0 (Table 2).

[0408] Table 2. Preparation system of 2M TEAB (pH 7.0)

[0409] Taking the preparation of 1L Buffer A (reverse phase) as an example, accurately measure 50mL of 2M TEAB stock solution using a 1L graduated cylinder, then weigh 240g of urea, add ultrapure water to make up to 1L, and store at room temperature. The appropriate preparation volume can be selected according to the required amount (Table 3).

[0410] Table 3 Buffer A (Inverted) Preparation System

[0411] Buffer B (Reversed Phase): 100mM TEAB + 4M urea in 50% ACN (Chromatographic Acetonitrile) (pH 7.0)

[0412] Taking the preparation of 1L Buffer B (reverse phase) as an example, accurately measure 50mL of 2M TEAB using a 1L graduated cylinder, weigh 240g of urea, add 450mL of ultrapure water, and then add anhydrous acetonitrile to bring the volume to 1L. Store at room temperature. The appropriate preparation volume can be selected according to the required amount (Table 4).

[0413] Table 4 Buffer B (Inverted) Preparation System

[0414] After the above experimental conditions were prepared, the following purification conditions were selected to carry out the crude product after amphiphilization, i.e., HPLC-plus reverse phase purification.

[0415] Table 5 Reverse-phase purification gradient

[0416] After HPLC purification, the main peak in the red box area of ​​the chromatogram is collected and subjected to Urea-PAGE detection and analysis, which is the HPLC-plus result in the biparent purification PAGE chromatogram.

[0417] The purity assay results of the affinity purification PAGE are shown in Figure 3B. As shown in the figure, affinity purification can improve the purification effect.

[0418] Example 4: Synthesis of other modified monomers

[0419] 5'-DMT-2'-Silyl-SS-Phosphoramidite Synthesis Path

[0420] Synthetic route: Step 1: Uracil nucleoside I reacts with TIPSCl2 to generate cyclosilyl ether intermediate II; Step 2: Intermediate II reacts with dichlorodimethylsilane under alkaline conditions to generate intermediate III; Step 3: Intermediate III reacts with 3-chloro-2-methyl-1-propene under castor catalysis to generate intermediate IV; Step 4: Intermediate IV reacts with a disulfide-bonded hydroxyl carbon chain under NaH to generate intermediate V; Step 5: Intermediate V undergoes decyclosilyl group removal under NEt3·3HF to generate intermediate VI; Step 6: Intermediate VI reacts with DMTr-Cl to generate DMTr-protected intermediate VII at position 5; Step 7: Intermediate VII undergoes reaction with tetrazolium and bis(diisopropylamino)(2-cyanoethoxy)phosphine to generate the final phosphoramidite monomer VIII (i.e., 5'-DMT-2'-Silyl-SS-Phosphoramidite).

[0421] 5'-silyl-2'-ACE-SS-Phosphoramidite Synthetic Path

[0422] Synthetic route: Step 1: Uracil nucleoside I reacts with TIPSCl2 to generate cyclosilyl ether intermediate II; Step 2: Intermediate II reacts with 2,2',2”-[methylenetri(oxo)]triethanoltriacetate under PPTS catalysis to generate intermediate III; Step 3: Intermediate III reacts with a hydroxyl carbon chain containing a disulfide bond under PPTS catalysis to generate intermediate IV; Step 4: Intermediate IV undergoes decyclosilyl group removal under NEt3·3HF to generate intermediate V; Step 5: The hydroxyl group at position 5 of intermediate V reacts with a chlorosilane to generate intermediate VI; Step 6: Intermediate VI is reacted with tetrazolium and bis(diisopropylamino)(2-cyanoethoxy)phosphine to generate the final phosphoramidite monomer VII (i.e., 5'-silyl-2'-ACE-SS-Phosphoramidite).

[0423] 5'-DMT-2'-Bn-TCO-Phosphoramidite Synthetic Path

[0424] Synthetic route: Step 1: react p-hydroxybenzoic acid CL3 with Bocamine, followed by HCl treatment to obtain amide condensation product CL1; Step 2: react condensation product CL1 with a pre-prepared trans-TCO-NHS ester to generate side chain CL; Step 3: react uracil nucleoside I with TIPSCl2 to generate cyclosilyl ether intermediate II; Step 4: react intermediate II with TBSCl to generate intermediate III with TBS at position 2; Step 5: selectively remove the cyclosilyl group from intermediate III at room temperature via NEt3·3HF to generate intermediate IV; Step 6: react intermediate IV with DMTr-Cl to generate intermediate V protected by DMTr at position 5; Step 7: react intermediate V with diisopropylphosphorus chloride reagent to generate intermediate VI; Step 8: react intermediate VI with the previously synthesized side chain CL under tetrazolium catalysis to generate the final phosphoramidite monomer VII (i.e., 5'-DMT-2'-Bn-TCO-Phosphoramidite).

Claims

1. A compound of formula I, wherein, R is a fluorescent group, or is a structure as shown in formula (II) Ra, Rb, Rc, Rd are each independently H, halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl; R3 is hydrogen, halogen, hydroxyl, C1-C6 alkoxy, or substituted C1-C6 alkoxy; R2and R4are each hydroxyl, hydrogen, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, or substituted C1-C6alkoxy, a phosphoric acid group, or a hydroxyl protecting group, or a structure as shown in formula (III), wherein: R 41 and R 42 each independently is hydroxyl, thiol, amino, protected hydroxyl, protected thiol, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, substituted C1-C6alkoxy, protected amino, or substituted amino; R 43 is O or S; R 44 is a bond, -O-, C1-C6alkyl, substituted C1-C6alkyl, C2-C6alkenyl, or substituted C2-C6alkenyl, and n2 is 0 or 1. R5 is a base moiety; A is a leaving group, A is attached to a hydroxyl or amino group in R; L is a chemical bond or a linker, linking A and B; B is a coupling reaction group or a solid phase; R6is O, S, -C(R 61 )(R 62 )- or -O-C(R 61 )(R 62 )-, R 61 and R 62 are each independently H, halogen, C1-C6alkyl, substituted C1-C6alkyl, C1-C6alkoxy, substituted C1-C6alkoxy, C2-C6alkenyl, substituted C2-C6alkenyl, C2-C6alkynyl or substituted C2-C6alkynyl.

2. The compound of claim 1 selected from one of the following:

3. The compound of claim 1, wherein A is a crosslinking group of a hydroxyl protecting group or a crosslinking group of an amino protecting group.

4. The compound of claim 3, wherein the hydroxyl protecting group is an ether protecting group or an ester protecting group.

5. The compound of claim 4, the hydroxyl protecting group is an ether protecting group, which includes an alkoxyalkyl ether protecting group, an alkyl ether protecting group, a silyl ether protecting group.

6. The compound of any one of claims 3-5, wherein the alkyl ether protecting group includes methyl, isopropyl, t-butyl, allyl, benzyl, p-methoxybenzyl, trityl.

7. The compound of any one of claims 3-5, wherein the alkoxyalkyl ether protecting group includes methoxymethyl (MOM), benzyloxymethyl (BOM), trimethylsilyl ethoxymethyl (SEM), 2-tetrahydropyranyl (THP), p-methoxybenzyloxymethyl (PMBM), methoxyethoxymethyl (MEM), methylthiomethyl (MTM), 2-(trimethylsilyl)ethoxymethyl (SEM).

8. The compound of any one of claims 3-5, wherein the silyl ether protecting group includes trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), t-butyldimethylsilyl (TBS), t-butyldiphenylsilyl (TBDPS).

9. The compound of claim 3, the hydroxyl protecting group is an ester protecting group, which includes a carboxylic acid ester protecting group, a carbonate ester protecting group, a sulfonic acid ester protecting group.

10. The compound of claim 9, wherein the carboxylic acid ester protecting group includes acetyl (Ac), benzoyl (Bz), pivaloyl (Piv).

11. The compound of claim 9, wherein the carbonate ester protecting group includes 9-fluorenylmethoxycarbonyl (-Fmoc), 2,2,2-trichloroethoxycarbonyl (-Troc).

12. The compound of claim 9, wherein the sulfonic acid ester protecting group includes methanesulfonyl (Ms), p-toluenesulfonyl (Ts).

13. The compound according to any one of claims 3-12, wherein the hydroxyl protecting group is selected from: methyl, ethyl, benzyl (Bn), phenyl, isopropyl, tert-butyl, allyl, cyclohexyl (cHex), methoxymethyl ether (MOM), 2-tetrahydropyran (THP), tert-butyldimethylchlorosilane (TBDMSCl), TBDPS, TBDMS, 4-methoxybenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-acyloxybenzyl, 2-methylphenyl, 2,6-dimethylphenyl, 2-chlorophenyl, pyridine-2-carboxylate, benzyl ether, p-methoxybenzyl ether, triphenylmethyl ether, diphenylmethyl, 4-methylthio-1-butyl, 2-(S-acetylthio) 2-Cyanoethyl, 2-cyano-1,1-dimethylethyl (CDM), 4-cyano-2-butenyl, 2-(trimethylsilyl)ethyl (TSE), 2-(phenylthio)ethyl, 2-(triphenylsilyl)ethyl, 2-(benzylsulfonyl)ethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,3-dibromopropyl, 2,2,2-trifluoroethyl, phenylthio, 2-chloro-4-triphenylmethylphenyl, 2-bromophenyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 4-(N-trifluoroacetylamino)butyl, 4-oxopentyl, 4-triphenylmethylaminophenyl, 4-benzylaminophenyl.

14. The compound of claim 3, wherein the amino protecting group is selected from: 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), tert-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc) and benzyloxycarbonyl (Cbz), formyl, acetyl, trihaloacetyl, benzoyl and nitrophenylacetyl, 2-nitrobenzenesulfonyl, phthalimide and dithiosuccinyl.

15. The compound of any one of claims 1-5, wherein B is an amino, hydroxyl, carboxyl, thiol, -S-S-(Ci-C 10 )alkyl group, aldehyde, ketone, azide, vinyl, acryloyl, thiolester, isocyanate, isothiocyanate, alkyl halide, sulfonyl halide, epoxide, imidoester, fluorophenyl ester, carbonate, carbodiimide, disulfide, aziridine, controlled-pore glass (CPC), polystyrene (PS), or a group that can undergo a coupling reaction with the aforementioned groups.

16. The compound according to any one of claims 1-15, wherein B is an amino group or a group capable of undergoing a coupling reaction with an amino group.

17. The compound of claim 16, wherein B is an amino group, an NHS ester, an imine ester, a pentafluorophenyl ester, or a hydroxymethylphosphine.

18. The compound according to any one of claims 1-15, wherein B is a carboxyl group or a group capable of undergoing a coupling reaction with a carboxyl group.

19. The compound of claim 18, wherein B is a carboxyl group or a carbodiimide.

20. The compound according to any one of claims 1-15, wherein B is a thiol group or a group capable of undergoing a coupling reaction with a thiol group.

21. The compound of claim 20, wherein B is a mercapto or maleimide, haloacetyl, pyridyldithiol, thiosulfonate, vinyl sulfone, -S-S-(C1-C 10 alkyl) group.

22. The compound according to any one of claims 1-15, wherein B is an aldehyde group or a group capable of undergoing a coupling reaction with an aldehyde group.

23. The compound of claim 22, wherein B is an aldehyde, hydrazide, alkoxyamine, or NHS ester.

24. The compound according to any one of claims 1-15, wherein B is an azide or a group capable of coupling with an azide.

25. The compound of claim 24, wherein B is an azide or a group containing an alkynyl group.

26. The compound of claim 25, wherein B is a tetrazine or a group that can react with a tetrazine.

27. The compound of claim 26, wherein B is a tetrazine, azide, TCO, DBCO, or BCN.

28. The compound according to claims 1-15, wherein B is 4-formylbenzoate (4FB) or hydrazinotinamide (HyNic).

29. The compounds of claims 1-15, wherein R is a fluorescent group, including but not limited to FAM, HEX, TAMRA, Cy3, Cy5, FITC, VIC, TET, JOE, ROX, Texas Red, Atto 488, Atto 565, Atto 647N, hydroxycoumarin, methoxycoumarin, Alexa fluor, aminocoumarin, Cy2, FAM, Alexa fluor 488, Fluorescein FITC, Alexa fluor 430, JOE, TET, Alexa fluor 532, HEX, VIC, Cy3, TRITC, Alexa fluor 546, Alexa fluor 555, R-phycoerythrin (PE), Rhodamine Red-X, TAMRA, Cy3.5, Rox, Alexa fluor 568, Red 613, Texas Red, Alexa fluor 594, Alexa fluor 633, Allophycocyanin, Alexa fluor 633, Cy5, Alexa fluor 660, Cy5.5, TruRed, Alexa fluor 680, NED, SYBR Green I and Cy7.

30. The compound according to any one of claims 1-29, wherein L is -(C(R) Xa (R) Xb )) n -, where when L contains a methylene unit, each of the zero or at least one methylene unit of L is independently controlled by -N(R) Xc )C(O)-、-C(O)N(R Xc )-, -C(O)-, -OC(O)-, -C(O)O-, -NR Xc -, -O-, -S-, -SO-, -SO2-, -P(R Xc )-、-P(=O)(R Xc )-、-N(R Xc SO2-, -SO2N(R) Xc -, -C(=S)-, -C(=NR) Xc -, -N=N-, -C=N-, -N=C- or -C(=N2)- are substitutes; where each R Xa R Xb R Xc Each of these can be independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H, or C 1-6 Aliphatic group, where n is an integer from 0 to 10.

31. The compound of any one of claims 1-30, L is -L 1 -L 2 -L 3 -, wherein -L 1 - is a bond, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -C(O)O-, -NH-, -O-, -S-, -SO-, -SO2-, -P(=O)(R Xc )-, -N(R Xc )SO2-, -SO2N(R Xc )-, -C(=S)-, -C(=NR Xc )-, -N=N-, -C=N-, -N=C-, or -C(=N2)-; - L 2 - is -(CH2)nL2- wherein nL2is an integer from 0 to 10; wherein -L 3 - is a bond, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -C(O)O-, -NH-, -O-, -S-, -SO-, -SO2-, -P(=O)(R Xc )-, -N(R Xc )SO2-, -SO2N(R Xc )-, -C(=S)-, -C(=NR Xc )-, -N=N-, -C=N-, -N=C- or -C(=N2)-.

32. The compound of any one of claims 1-31, wherein, When A is attached to a hydroxyl or phosphate group, the structure of -A- is one of the following The asterisk (*) represents the part that connects to the oxygen atom.

33. The compound of any one of claims 1-30, wherein, When A is a linking base, the structure of -A- is one of the following, wherein "*" represents the exocyclic amino group of the linking base, The asterisk (*) represents the part that connects the bases.

34. The compound of any one of claims 1-32, wherein, The -B structure is one of the following: (CH2) m S-S-, -SH, -NH2, -COOH Where m is an integer from 1 to 10.

35. The compound according to any one of claims 1-33, wherein the base moiety is pyrimidine, substituted pyrimidine, pseudouracil, substituted pseudouracil, purine, hypoxanthine, or substituted purine.

36. The compound of claim 34, wherein, The bases are selected from one or more of the following groups: Xanthine, Allylaminouracil, Allylaminothymidine, Hypoxanthine, Dioxetidine, Dioxycytidine, Dioxoguanine, Dioxouracil, 6-Chloropurine nucleoside, N6-Methyladenine, Methylpseudo-uracil, 2-Thiocytosine, 2-Thiouracil, 5-Methyluracil, 4-Thiothymidine, 4-Thiouracil, 5,6-Dihydro-5-methyluracil, 5,6-Dihydrouracil, 5-[(3-indolyl)propionamido-N-allyl]uracil, 5-Aminoallylcytosine, 5-Aminoallyluracil, 5-Bromouracil, 5-Bromocytosine, 5-Carboxycytosine, 5-Carboxyuracil, 5-Fluorouracil, 5-Formylcytosine, 5-Formyluracil, 5-Hydroxycytosine, 5-Hydroxymethylcytosine, 5-Hydroxymethyluracil, 5-Hydroxyuracil, 5-Iodocytosine, 5-Iodouracil, 5-Methoxycytosine, 5-Methoxyuracil, 5-Methylcytosine, 5-Methyluracil, 5-Propynylaminocytosine, 5-Propynylaminouracil, 5-Propynylcytosine, 5-Propynyluracil, 6-Azacytosine, 6-Azauracil, 6-Chloropurine, 6-Thioguanine, 7-Deazanucleoside, 7-Deazaguanine, 7-Deaza-7-propylaminoadenine, 7-Deaza-7-propynylaminoadenine, 8-Azadenine, 8-Azidoadenine, 8-Chloroadenine, 8-Oxoadenine, 8-Oxoguanine, Biotin-16-aminoallylcytosine, Biotin-16-aminoallyluracil, Cytosine, Guanine, Uracil,6-diaminoguanine, 5-formamidouracil, 5-ethynyluracil, N6-iso-pentenyladenine (i6A), 2-methylthio-N6-iso-pentenyladenine (ms2i6A), 2-methylthio-N6-methyladenine (ms2m6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycinamidoformyladenine (g6A), N6-threoninamidoformyladenine (t6A), 2-methylthio-N6-threoninamidoformyladenine (ms2t6A), N6-methyl-N6-threoninamidoformyladenine (m6t6A), N6-hydroxynalanylaminomethyladenine (hn6A), 2-methylthio-N6-hydroxynalanylaminomethyladenine (ms2hn6A), N6,N6-dimethyladenine (m62A), and N6-acetyladenine (ac6A).

37. An oligonucleotide comprising the compound as described in any one of claims 1-36.

38. A method for preparing a target nucleic acid, comprising: (1) Providing an extractable fragment having an affinity structure, the affinity structure comprising a compound as described in any one of claims 1-36, wherein functional group B is an affinity-modified compound. (2) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected; (3) The extracted fragments were fixed onto the stationary phase by connecting affinity-modified structures and fixation-modified structures; (4) Provide an intermediate segment and connect the intermediate segment to the end of the extracted segment; (5) Separate the target nucleic acid from the stationary phase.

39. A method for preparing a target nucleic acid, comprising: (1) Provide one or more extractable fragments and one or more intermediate fragments, wherein the extractable fragments contain a compound as an affinity structure as claimed in any one of claims 1-36, wherein functional group B is an affinity modification; (2) Connect one or more extracted fragments and one or more intermediate fragments to form a mixture of nucleic acid fragments; (3) A stationary phase is provided, wherein the surface of the stationary phase has a fixation modification, wherein the affinity modification and the fixation modification can be covalently or non-covalently connected; (4) By linking the affinity modification and the fixation modification, the nucleic acid fragment containing the target nucleic acid in the nucleic acid fragment mixture is bound to the surface of the stationary phase; (5) Separate the target nucleic acid from the stationary phase.

40. The method according to claim 38, wherein the extracted fragment comprises a first extracted fragment and a second extracted fragment. The first extracted fragment includes a first affinity structure, and the first affinity structure includes a first affinity modification; The second extracted fragment includes a second affinity structure, and the second affinity structure includes a second affinity modification; The first affinity modification and the second affinity modification are different.

41. The method according to any one of claims 37-38, wherein the stationary phase comprises a first stationary phase and a second stationary phase. The first fixed phase includes a first fixed modification, wherein the first affinity modification and the first fixed modification can be covalently or non-covalently connected; The second stationary phase includes a second stationary modification, wherein the second affinity modification and the second stationary modification can be covalently or non-covalently linked.

42. The method according to claims 37-40, wherein the extracted fragment and / or intermediate fragment is a single-stranded nucleic acid fragment or a double-stranded nucleic acid fragment.

43. The method of claim 36, wherein the extracted fragment and / or intermediate fragment is a single-stranded DNA fragment or an RNA fragment.

44. The method of claim 36, wherein the extracted fragment and / or intermediate fragment is a DNA double-stranded fragment, an RNA double-stranded fragment, or an RNA / DNA hybrid fragment.

45. The method according to claims 32-38, wherein one or both ends of the extracted segment and / or intermediate segment have a protruding structure, wherein the length of the protruding structure is 2-200 nt.

46. ​​The method according to claims 33-39, wherein the affinity modification and the fixation modification can be covalently linked.

47. The method of claim 40, wherein the covalent connection forms a linker, the linker comprising an amino-reactive linker, a carboxyl-amino-reactive linker, a thiol-reactive linker, an aldehyde-reactive linker, a photoreactive linker, or an azide-reactive linker.

48. The method according to claim 40, wherein the linker is an amino-reactive linker, including NHS esters, imine esters, pentafluorophenyl esters, or hydroxymethylphosphine.

49. The method of claim 40, wherein the linker is a thiol-reactive class of linkers, including maleimide, haloacetyl (bromo-, chloro- or iodo-), pyridyldithiol, thiosulfonate, vinyl sulfone, -S-S-(C1-C 10 alkyl) groups.

50. The method of claim 40, wherein the linker is an aldehyde-based reactive class of linker, including hydrazide, alkoxyamine, NHS ester.

51. The method of claim 40, wherein the linker is a photo-reactive class of linker, including diazirine, aromatic azide.

52. The method of claim 40, wherein the linker is a click chemistry class of linker.

53. The method of any one of claims 32-46, wherein the affinity structure at the 5' end or 3' end of the extracted fragment is located on the 2' carbon of the 5' terminal or 3' terminal nucleotide.

54. The method of any one of claims 32-47, wherein the affinity structure is a polynucleotide, the affinity structure comprising a compound as in any one of claims 1-30, the compound being at the 5' end or 3' end of the polynucleotide, or located between the 5' end and the 3' end.